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Treatment-emergent metabolic syndrome is an established risk factor for cardiovascular 
disease known to be associated with cognitive impairment, poor functioning and decreased 
quality of life in schizophrenia spectrum disorders. However, weight gain and increased 
lipids have also been correlated with clinical improvement in chronic schizophrenia patients. 
While most studies investigating the relationships between body mass and treatment 
outcome were conducted in patients treated with clozapine and olanzapine, it remains 
unclear to what extent the role of weight gain as a predictor of favourable clinical outcomes 
extends to include illness-specific symptom domains in first-episode patients treated with 
other antipsychotics with a lower obesogenic potential. The effects of other clinical (e.g. sex, 
substance use, baseline body mass) and treatment-related (e.g. antipsychotic dose, 
medication adherence) confounders on the above relationships is also unclear. In response 
to these knowledge gaps, the overarching aim of our doctoral studies was to explore the 
temporal evolution of metabolic syndrome risk factors and their effects on clinical outcome 
over 12 months of treatment in first-episode schizophrenia spectrum disorder patients.  
We found that an increase in body mass correlates with global psychopathology 
improvement as well as the disorganized symptoms domain of schizophrenia in first-episode 
patients (n=106) over 12 months of treatment, independent of the degree of antipsychotic 
exposure (sub-study I). The association between weight gain and clinical improvement 
extended to include better overall end-point cognition after 12 months of treatment in our 
first-episode patient cohort (n=72) (sub-study II). A differential effect for lower baseline body 
mass index as a predictor of end-point working memory performance was evident in 




The adverse role of low body mass index as an unfavourable prognostic marker was further 
substantiated by its associations with an earlier age of psychosis onset and more severe 
negative symptoms in first-episode patients (n=69) (sub-study III). The inclusion of a 
diffusion tensor imaging component to our research also revealed a similar differential 
association of body mass index with fronto-limbic white matter fractional anisotropy (FA) in 
first-episode patients (low body mass index, low FA) versus healthy controls (high body 
mass index, low FA) adjusting for age and sex (sub-study III). Extension of our structural 
neuroimaging research to include brain structures involved in the physiological, hedonic and 
cognitive control as part of a “core eating network” further identified smaller anterior 
hippocampal volumes as a sex-specific predictor of weight gain in first-episode patients 
(n=90) (sub-study IV).  
Our research supports the role of weight gain as a predictor of favourable clinical outcomes 
in first-episode schizophrenia patients for whom treatment adherence is assured. In contrast, 
low body mass and by extension failure to gain weight could represent an unfavourable 
prognostic marker in first-episode patients, particularly those who use substance users. 
Future studies would do well to combine clinical, biological and neuroimaging data in order 












Metaboliese sindroom sekondêr to behandeling is ’n belangrike risikofaktor vir 
kardiovaskulêre siekte wat verbind word met kognitiewe aantasting, swak funksionering en 
’n afname in lewensgehalte by skisofrenie spektrum steurings. ’n Toename in gewig en 
lipiede is egter ook al verbind met kliniese verbetering in pasiënte met chroniese skisofrenie. 
Terwyl meeste studies wat die verhouding tussen liggaamsmassa en uitkoms ondersoek 
gedoen is met pasiënte wat met klosapien en olansapien behandel is, is dit onduidelik tot 
watter mate die rol van gewigstoename as ’n voorspeller van gunstige kliniese uitkomste 
verder strek om siekte-spesifieke simptoomdomeine in te sluit in eerste-episode pasiënte 
wat met ander antipsigotiese middels met ’n laer obesogeniese potensiaal behandel word. 
Die uitwerking van ander kliniese (bv. geslag, middelgebruik, basislyn liggaamsmassa) en 
behandelings-verwante (bv. die dosis van antipsigotiese middels, hoe getrou medikasie 
gebruik word) faktore op bogenoemde verband is ook onduidelik. In reaksie op hierdie 
leemtes in kennis was die oorkoepelende doel van die doktorale studie om die temporele 
ontwikkeling van risikofaktore vir metaboliese sindroom te ondersoek asook die uitwerking 
daarvan op kliniese uitkoms oor 12 maande van behandeling in pasiënte met ’n eerste-
episode van skisofrenie spektrum steurnisse.   
Ons het gevind dat ’n toename in liggaamsmassa verband hou met algemene 
psigopatologiese verbetering sowel as die gedisorganiseerde simptoomdomein van 
skisofrenie in eerste-episode pasiënte (n=106) oor 12 maande van behandeling, onafhanklik 
van die graad van antipsigotiese blootstelling (substudie I). Die verband tussen 
gewigstoename en kliniese verbetering het ook beter algemene eindpunt kognisie na 12 
maande van behandeling in ons groep eerste-episode pasiënte ingesluit (n=72) (substudie 
II). Daar was ook ‘n differensiële effek vir laer basislyn liggaamsmassaindeks as ’n 
voorspeller van eindpunt-werkgeheue prestasie in middelgebruikers (ongunstig) in 




Die nadelige rol van lae liggaamsmassaindeks as ’n ongunstige prognostiese merker was 
ook gestaaf deur die verbintenis daarvan met ’n vroeër ouderdom waarop psigose begin het 
en ernstiger negatiewe simptome in eerste-episode pasiënte (n=69) (substudie III). Die 
insluiting van ’n diffusie tensor beelding komponent by ons navorsing het ook ’n soortgelyke 
onderskeidende verbintenis onthul tussen liggaamsmassaindeks en fraksionele anisotropie 
(FA) van frontaal-limbiese witstof in eerste-episode pasiënte (lae liggaamsmassaindeks, lae 
FA) teenoor gesonde kontroles (hoë liggaamsmassaindeks, lae FA) met aanpassings vir 
ouderdom en geslag (substudie III). ’n Uitbreiding van ons navorsing oor strukturele 
neurobeelding om breinstrukture in te sluit wat betrokke is by fisiologiese, hedoniese en 
kognitiewe beheer as deel van ’n “kern-eetnetwerk” het kleiner volumes van die anterior 
hippokampus verder geïndentifiseer as ’n geslag-spesifieke voorspeller van gewigs toename 
in eerste-episode pasiënte (n=90) (substudie IV).  
Ons navorsing ondersteun die rol van gewigstoename as ’n voorspeller van gunstige kliniese 
uitkomstes in pasiënte met ’n eerste episode van skisofrenie wie se getroue volging van 
behandeling verseker word. In teenstelling hiermee kan ’n laer liggaamsmassa en by 
uitbreiding die versuim om gewig aan te sit ’n ongunstige prognose merker wees in eerste-
episode pasiënte, veral in die wat middels gebruik. Dit sal goed wees as toekomstige studies 
kliniese, biologiese en neurobeeldings data kan kombineer met die oogmerk om intrinsieke 
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This chapter provides a contextualized overview of the research topic for doctoral studies 
described in this dissertation, focusing on the associations between weight gain and 
treatment outcome in first-episode schizophrenia spectrum disorders. The problem 
statement and study rationale are then described, followed by a formulation of the research 
aim, corresponding study objectives, and relevant hypotheses. The structure of the 
dissertation is also outlined, followed by a description of the research contributions of the 
doctoral candidate. 
1.1. Weight Gain in First-Episode Schizophrenia  
Individuals living with schizophrenia are at an elevated risk for early demise, translating into 
an approximately 10-25 year lower life expectancy (Saha et al., 2007; Laursen et al., 2012). 
There are multiple reasons for the increased mortality gap evident between schizophrenia 
patients and the general population, including accidental causes such as suicide, as well as 
a higher prevalence of substance abuse (Laursen et al., 2012). In particular, comorbid 
illnesses such as cardiovascular disease are recognized as a major cause of premature 
death in schizophrenia spectrum disorders (Hennekens et al., 2005; Saha et al., 2007).  
In this context, the metabolic syndrome and its constituent components are well-known risk 
factors for ischemic heart disease and adverse cardiac events both in schizophrenia patients 
and non-affected individuals (Hennekens et al., 2005). In addition to genetics, lifestyle and 
dietary factors, antipsychotic use has emerged as a notable cause of treatment-emergent 
metabolic syndrome in schizophrenia spectrum disorders (Riordan et al., 2011; Mitchell et 
al., 2013). There is marked variation in the metabolic side-effect profiles of different 
antipsychotics (de Hert et al., 2012; Pillinger et al., 2020). The second-generation drugs 
clozapine and olanzapine are particularly well known for their high propensity to induce 
weight gain and associated metabolic changes (de Hert et al., 2012; Mitchell et al., 2013). 




gain if treatment exposure is sufficient (de Hert et al., 2012; Bak et al., 2014). Indeed, other 
medications such as zipradisone, despite an apparent favourable effect on lipid profiles, 
have been linked to the development of non-alcoholic fatty liver disease as the hepatic 
expression of the metabolic syndrome (Morlan-Coarasa et al., 2016).  
In first-episode schizophrenia patients, initial short-term exposure to treatment confers 
significant risk for weight gain (Mitchell et al., 2013). In many cases, weight gain is expected 
to be early and pronounced, developing as soon as two weeks after the initiation of 
antipsychotic treatment (Chadda et al., 2013), and most commonly being clinically apparent 
within the first six months of therapy (Attux et al., 2007). Further metabolic deterioration is 
often rapid, particularly if compounded by co-treatment with mood stabilizers or 
antidepressants (Bioque et al., 2018). Initial short-term studies reported that weight gain in 
first-episode cases levels off or stops within the first to second year of treatment (Umbricht et 
al., 1994; Allison et al., 2009).  While long-term outcome data remains scarce, there is also 
evidence to suggest that weight gain continues for years or even decades after the initiation 
of treatment (Strassnig et al., 2017). The risk for other metabolic complications such as 
Insulin Resistance (IR) and type II Diabetes Mellitus (DM II) increases significantly with 
ongoing antipsychotic use (Jeong et al., 2018) and is primarily elevated over the long-term, 
chronic course of treatment (Pillinger et al., 2017).  
The development of weight gain and associated metabolic syndrome changes over the 
course of antipsychotic treatment is therefore a common occurrence in first-episode 
schizophrenia spectrum disorders. However, certain metabolic syndrome abnormalities are 
already present in treatment-naive patients (Freyberg et al., 2017). Indeed, several cross-
sectional studies have reported a higher prevalence of metabolic syndrome as composite 
entity in first-episode patients versus controls (Darcin et al., 2015; Fawzy et al., 2015). 
However, this finding has not been replicated in all studies to date (Chiliza et al., 2015a; 
Rawat et al., 2018). Nevertheless, a majority of schizophrenia patients (~60%) will present 




et al., 2018) even if full diagnostic criteria are not met. In particular, systematic reviews and 
meta-analyses support the existence of increased waist circumference, impaired glucose 
tolerance and lipid abnormalities consistent with the metabolic syndrome in first-episode 
patients with minimal prior treatment exposure (Petrikis et al., 2015; Misiaket al., 2017; 
Pillinger et al., 2017; Petruzzelli et al., 2018). Metabolic syndrome abnormalities have also 
been described in first-degree relatives of patients with schizophrenia (Darcin et al., 2015; 
Jensen et al., 2017; Choiunard et al., 2018) as well as individuals at clinical high-risk for 
developing a first-episode of psychosis (Cordes et al., 2017).  
From converging lines of evidence, studies to date could support the notion that certain 
metabolic syndrome features known to arise secondary to pharmacotherapy in 
schizophrenia patients, are already present in first-episode, treatment-naive cases. In this 
context, certain metabolic syndrome features present in treatment-naive patients might be 
considered as intrinsic to the illness itself (Freyberg et al., 2017). 
1.2. Body Mass and Treatment Outcome in First-Episode Schizophrenia 
Treatment-emergent metabolic syndrome is thus recognized as an important contributor to 
excess mortality risk in schizophrenia (Hennekens et al., 2005; Saha et al., 2007). This 
motivates the need to predict both clinical outcome and side-effect burden in affected 
patients (Riordan et al., 2011). Indeed, failure to detect and manage metabolic syndrome 
risk factors early on could increase the chance for poor long-term outcomes as the illness 
progresses (Vancampfort et al., 2015). On the one hand, risk for the development of 
metabolic syndrome is increased in chronic compared to first-episode schizophrenia patients 
(Vamcampfort et al., 2013). On the other, first-episode patients are also at substantial risk for 
weight gain, despite showing an overall favourable response to treatment (Karson et al., 
2016). It is therefore important for clinicians to balance clinical efficacy with the mitigation of 
treatment-emergent side-effects including metabolic syndrome changes irrespective of the 




Cardiovascular risk monitoring is thus often incorporated as a component of patient care in 
an attempt to mitigate or prevent treatment-emergent metabolic syndrome changes 
(Phutane et al., 2011). International guidelines are also now in place to support the more 
widespread adoption of screening and monitoring programs for cardio-metabolic risk factors, 
which remain both under-diagnosed and undertreated in chronic schizophrenia (Ventriglio et 
al., 2015; Lappin et al., 2018). Emphasis is often placed on extensive metabolic risk 
screening and monitoring following initial exposure to treatment, viewed as a “critical period 
for prevention” of cardiovascular disease (Phutane et al., 2011). In an attempt to guide 
clinicians, much research has been conducted in an attempt to identify, characterize and 
validate accurate, appropriate and cost-effective predictors of treatment outcome in 
schizophrenia (Carbon and Correll 2014; Santesteban-Echarri et al., 2017). Interestingly, 
since antipsychotics with a high potential to induce weight gain are often those with superior 
clinical efficacy in resistant cases of schizophrenia (Leucht et al., 2013), socio-demographic 
and clinical predictors of clinical response often overlap with those for metabolic side-effects 
(Pillinger et al., 2020). However, very little is known about the role of anthropometric, 
metabolic, biological and blood-based biomarkers in the prediction of clinical outcome in 
first-episode schizophrenia (Fond et al., 2015; Mondelli et al., 2015).  
Nevertheless, there is evidence to suggest that antipsychotic-induced metabolic syndrome 
changes including weight gain influence the clinical response to treatment both in first-
episode (Nettis et al., 2019) and chronic schizophrenia (Godin et al., 2018). In a similar 
fashion, increased body mass has been correlated with disease chronicity, rapid cycling, a 
longer duration of illness, treatment non-response, and poorer functional outcomes in bipolar 
disorder (Fagiolini et al., 2003; Calkin et al., 2009, 2015). In addition, some (Green et al., 
2017) but not all (Angstman et al., 2013; Mansoor et al., 2013; Sahle et al., 2019) studies 
have identified weight gain as a predictor of treatment outcome in patients with major 
depressive disorder. The purported unfavourable association of metabolic syndrome 




intuitive. After all, studies have often linked metabolic syndrome risk factors with more 
severe prodromal symptoms in those at-risk for schizophrenia (Cadenhead et al., 2019), 
earlier age of onset in newly diagnosed patients (Nadalin et al., 2018), as well as more 
severe negative psychopathology, and deficit-type symptoms in chronic schizophrenia 
(Arango et al., 2008, 2011; Sicras-Mainar et al., 2014). In a similar fashion, antipsychotic-
induced metabolic changes including weight gain have been shown to negatively affect 
physical health, cognitive outcomes, level of functioning and quality of life in chronic patients 
(Agid et al., 2013; Kritharides et al., 2017).  
However, there is an opposing body of evidence which rather positions increased body mass 
as a favourable prognostic marker in the management of schizophrenia. This notion, while 
apparently counterintuitive, is not without merit. Indeed, Bleuler was among the first to 
describe abnormalities of appetite and eating behaviours in schizophrenia back in the 19th 
century (Hoff, 2012). In the early 20th century, reports of an association between 
spontaneous recovery and weight gain started to emerge (Kalinowsky, 1948). It was during 
the era of first-generation antipsychotics that the potential role of weight gain as a favourable 
predictor of treatment response fully started to emerge (Planansky, 1958). In more recent 
decades, further evidence has emerged to suggest that weight gain related to antipsychotic 
use is associated with general clinical improvement and overall therapeutic benefit (Sharma 
et al., 2014).  
In a systematic review of 31 independent research studies conducted by Raben and 
colleagues (2017), the authors demonstrated a favourable association between weight gain 
and clinical outcome, which was largely independent of age, sex, level of compliance, and 
prior exposure to treatment, i.e. also being present in first-episode patients. In comparison, 
both the use of second-generation antipsychotics with a high obesogenic potential (i.e. 
clozapine, olanzapine) and the duration of current treatment moderated the relationship 
between weight gain and clinical improvement (Raben et al., 2017). In a more recent 




Pillinger et al., (2020), the authors also demonstrated that an increase in body mass index 
correlated with an incremental reduction in global psychopathology. In summary, metabolic 
assessment may have important implications for the management of schizophrenia beyond 
its more established role in cardiovascular risk management. In particular, cardio-metabolic 
risk assessment could help guide and optimize patient care by facilitating the identification of 
important prognostic subtypes (Freyberg et al., 2017). 
1.3. Problem Statement and Study Rationale  
Several important challenges remain in establishing the prognostic relevance of metabolic 
syndrome and its constituent components as markers of treatment outcome in schizophrenia 
spectrum disorders.  
First, most studies reporting an association between weight gain and clinical improvement 
have focused on global measures of illness severity in chronic patients treated with the 
second-generation antipsychotics clozapine and olanzapine (Sharma et al., 2014; Raben et 
al., 2017). It is therefore unclear whether the purported favourable effects of weight gain on 
clinical outcome are illness-specific, and extend to include first-episode patients treated with 
other antipsychotics.  
Second, the majority of prior outcome studies have not comprehensively accounted or 
controlled for either the degree of treatment exposure, or adherence to medication. This is 
important, since weight gain may be a risk factor for treatment non-adherence. On the other 
hand, higher rates of adherence may be related to the clinical efficacy of treatment, but also 
a greater likelihood of metabolic side-effects including weight gain, which in turn again poses 
risk for non-compliance (Higashi et al., 2013). Despite differences in metabolic risk profile 
across antipsychotics of different classes, the formulation of a specific medication (oral vs. 
long-acting injectable antipsychotic) does not appear to constitute a major individual 




Third, it remains unclear to what extent researchers should consider the manner in which 
baseline metabolic status could influence the inter-play between treatment-emergent 
metabolic syndrome changes, symptom trajectories and attainment of meaningful clinical 
outcomes (Raben et al., 2017). This topic warrants attention, since metabolic syndrome risk 
factors are not only common in schizophrenia patients, but appear to cluster based on 
specific clinical traits (Arango et al., 2008, 2011; Nadalin et al., 2018; Cadenhead et al., 
2019). In particular, the apparent overlap between increased body mass and negative 
symptoms irrespective of disease stage could have important implications for treatment 
(Sicras-Mainar et al., 2014; Mezquida et al., 2018). 
Lastly, the different factors underscoring the purported relationships between weight gain 
and different clinical, cognitive as well as functional aspects of outcome remain incompletely 
described. There is particular interest in biological and molecular mechanisms such as 
oxidative stress, chronic, low-grade inflammation (Mondelli and Howes 2014; Haring et al., 
2015), hypothalamic-pituitary-adrenal axis dysregulation (Mondelli and Pariante 2008) and 
abnormal regulation of hormones and adipokines involved in the regulation of appetite and 
satiety (Basoglu et al., 2010). In particular, little is known about the role of brain structure 
and white matter connectivity in relation to pre-treatment body mass, weight gain and clinical 
outcome in schizophrenia patients. This is important, since earlier studies have reported an 
association between metabolic syndrome risk factors and brain volumetric changes in first-











1.4. Aims and Objectives  
In response to these research challenges, the overarching aim of the doctoral studies 
described in this dissertation was to explore the temporal evolution of metabolic 
syndrome risk factors and their effects on clinical outcome over the first year of 
treatment in schizophrenia spectrum disorders in relation to their brain structural and white 
matter concomitants.  
The specific research objectives were as follows: 
• To examine the associations between treatment-emergent metabolic syndrome 
changes and psychopathology improvement over 12 months of treatment in first-
episode schizophrenia spectrum disorder patients in relation to age, sex, ethnicity, 
substance use, baseline metabolic status, and the degree of antipsychotic exposure 
(sub-study I) 
• To examine the associations between change in body mass over 12 months and 
end-point cognitive performance in first-episode schizophrenia spectrum disorder 
patients in relation to age, sex, substance use, baseline metabolic status, and the 
degree of antipsychotic exposure (sub-study II) 
• To examine the associations of body mass with brain structure and connectivity in 
first-episode schizophrenia spectrum disorder patients compared to otherwise 
healthy matched controls. In particular, we focused on fronto-limbic white matter 
tracts known to connect brain regions involved in the regulation of metabolism, 
appetite, satiety and reward as part of a “core eating network” (sub-study III) 
• To examine the associations of brain volumes for sub-cortical regions (including the 
thalamus, pallidum, putamen, caudate, ventral diencephalon, brainstem, amygdala, 
hippocampus, and nucleus accumbens) involvement in the cognitive, hedonic, 
emotional and physiological control of feeding behaviours in humans with weight gain 




1.5. Study Hypotheses  
1. Weight gain over the first 12 months of treatment in first-episode schizophrenia 
spectrum disorder patients will be associated with psychopathology improvement, 
largely independent of the degree of antipsychotic exposure (sub-study I) 
2. The association of weight gain with clinical improvement over the first 12 months 
of treatment in first-episode schizophrenia spectrum disorder patients will extend 
to include better end-point cognition (sub-study II) 
3. Lower baseline body mass will be differentially associated with fronto-limbic white 
matter fractional anisotropy (FA) in first-episode schizophrenia spectrum disorder 
patients (decreased body mass, decreased FA) versus healthy controls 
(increased body mass, decreased FA) for tracts which connect brain regions 
known to form part of a “core eating network” in humans (sub-study III) 
4. Impairment in brain structure and integrity at baseline will predict greater weight 
gain over the first 12 months of treatment in first-episode schizophrenia spectrum 
disorder patients, particularly for sub-cortical regions involved in the control of 















1.6. Outline and Structure of Dissertation  
The doctoral research described here was conducted as part of a larger single-site cohort 
study developed in order to explore the clinical, biological and functional aspects of 
treatment outcome in first-episode schizophrenia spectrum disorder patients. This parent 
project (EONCKS), first conceived and initiated in 2007, was named after the principal 
investigators of the study, viz. Professors Robin Emsley, Piet Oosthuizen, Dana Niehaus, 
Liezl Koen, Bonginkosi Chiliza, and Renata Schoeman. The first round of data collection was 
completed in 2011, which included comprehensive patient evaluation and follow-up over 
regular visits.  
In the this dissertation, research conducted over the course of my doctoral studies has been 
integrated and presented in the form of journal articles, all of which have been published in 
high-impact international journals (Table 1). In brief, the research described here is based 
around the temporal evolution of metabolic syndrome risk factors and their associations with 
clinical outcome over the first 12 months of treatment in schizophrenia spectrum disorder 
patients in relation to relevant brain structural concomitants. This research focus was 
motivated by the observation that initial exposure to treatment with flupenthixol decanoate in 
an overlapping first-episode patient cohort (n=107) resulted in significant weight gain, as well 
as elevated triglycerides and decreased high-density lipoprotein (HDL) cholesterol levels 
(Chiliza et al., 2015a). In addition, our focus on the effects of metabolic syndrome risk factors 
on clinical outcome was substantiated by the association evident between low body mass 
index and treatment non-response in first-episode schizophrenia spectrum disorders (n=126) 
(Chiliza et al., 2015b). Lastly, the decision to incorporate a neuroimaging component as part 
of the present research project was motivated by evidence from an initial pilot project, in 
which first-episode patients (n=22) exposed to three months of treatment with flupenthixol 
decanoate demonstrated an increase in body mass index, which in turn correlated with 




For each publication, I led the development of a research question and paper proposal, 
performed the initial statistical analyses, drafted the first manuscript, as well as edited and 
finalized the article for submission following co-author input. In addition, I assisted with pre- 
and post-processing of structural imaging data for the relevant studies of interest. In each 
sub-study, I was further presented with individual opportunities for research capacity and 
skills development. In particular, I focused on training in statistical analysis and 
interpretation, including linear regressions (Chapters II, III, and V), mixed effects models for 
continuous repeated measures (Chapter V), and multivariate analyses of covariance 
(Chapter IV).  
Chapter II is a first-author journal article published in the international journal Schizophrenia 
Research. In this publication, we describe a sub-study (I) in which we explored the 
associations between pre-treatment as well as treatment-emergent metabolic syndrome 
changes and psychopathology improvement over 12 months of treatment in first-episode 
schizophrenia spectrum disorder patients (n=106). To the best of our knowledge, this was 
the first study to demonstrate that treatment-emergent weight gain is associated with 
psychopathology improvement in first-episode patients treated with a relatively weight-
neutral depot antipsychotic, independent of age, sex, substance use, and the degree of 
antipsychotic exposure. This study provided the scientific rationale for further exploration of 
weight gain in relation to treatment outcomes in our patient cohort.  
Chapter III is a first-author journal article published in the international journal Metabolic 
Brain Disease. In this publication, we describe a sub-study (II) in which we sought to extend 
our initial research focus (Chapter II) to include the associations of body mass and weight 
gain with cognitive performance in first-episode schizophrenia spectrum disorder patients 
(n=72). We demonstrated that, in addition to psychopathology improvement, weight gain is 
associated with better end-point cognitive performance and the working memory domain 
over 12 months of treatment, independent of age, sex, and the degree of antipsychotic 




working memory performance in substance non-users, who gained significant body weight 
over the course of treatment. In contrast, high baseline body mass index appeared to have a 
protective effect in substance users, who showed prevalent weight loss, and a less 
pronounced increase in body weight, over the course of treatment.  
Chapter IV is a first-author journal article published in the international journal Psychiatry 
Research: Neuroimaging. In this publication, we describe a sub-study (III) in which we 
examined the neurobiological and brain white matter structural correlates of body weight in 
first-episode schizophrenia spectrum disorder patients (n=69) versus healthy controls 
(n=93). We showed that baseline body mass index is differentially associated with fronto-
limbic white matter fractional anisotropy (FA) in the two groups, with particular involvement 
of the corpus callosum (genu) and tapetum in patients (low body mass index, low FA) versus 
controls (high body mass index, low FA). In addition, lower body mass index was 
significantly correlated with an earlier age of onset as well as more severe negative 
symptoms, which were also inter-related. This study provided important evidence 
substantiating the involvement of brain structural integrity and connectivity underscoring the 
relationship between body mass and symptom expression in our first-episode patient 
sample. 
Chapter V is a first-author journal article published in the international journal Psychiatry 
Research: Neuroimaging. In this publication, we sought to build on our research described 
above by investigating the associations of body mass and weight gain with brain volumetric 
measures for sub-cortical regions implicated in the physiological (e.g. hypothalamus), 
cognitive-emotional (e.g. orbito-frontal and dorso-lateral prefrontal cortex, hippocampus, 
amygdala) and hedonic (e.g. ventral tegmental area, nucleus accumbens) control of eating 
(Chen et al., 2016) in first-episode patients (n=90) versus healthy controls (n=92). In this 
sub-study (IV), we focused on the hippocampus, a key brain region involved in the regulation 
of most aspects of eating behaviours in humans, and its individual subfields. Importantly, we 




predictors of change in body mass over 12 months, adjusting for age, substance use, and 
treatment duration. In an exploratory post-hoc sub-analysis, partial correlations showed a 
significant association between weight gain and smaller CA1, CA3 and subiculum volumes 
in females, but not males, adjusting for age and substance use, with similar trends evident 
for the CA4 and presubiculum subfields.  
Chapter VI presents a narrative synthesis of the most important insights gathered as a result 
of the doctoral research described in this dissertation. Future avenues for both local and 

















Table 1. Outline of sub-studies published as original first-author manuscripts in high-impact 
international journals. Information on the participants, relevant neuroimaging modality, and 
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Background: Treatment-emergent weight gain is associatedwith antipsychotic efficacy in schizophrenia patients
treated with clozapine and olanzapine. However, few studies have investigated this relationship in first-episode
patients treated with other antipsychotics, in particular those with a lower obesogenic potential.
Aim
To investigate the relationships between weight gain and associated metabolic changes with psychopathology
improvement in relation to age, sex, ethnicity, substance use, treatment duration and antipsychotic dose in
first-episode schizophrenia spectrum disorder patients.
Methods: This single site cohort study included 106 minimally treated or antipsychotic-naive patients treated
with flupenthixol decanoate over 12 months. Psychopathology was evaluated using the Positive and Negative
Syndrome Scale (PANSS) and BMI, fasting blood lipids and glucose were assessed at regular intervals. Linear re-
gression models were constructed to determine the effects of socio-demographic, clinical and metabolic factors
as predictors of change in total PANSS score and factor-derived domains.
Results: BMI change scores were inversely correlated with change in PANSS total (R = −0.25; p = 0.011), pos-
itive (R = −0.23; p = 0.019), depressive anxiety (R = −0.21; p = 0.031) and disorganized symptoms (R =
−0.32; p b 0.001). Linear regression analysis showed that increased BMI and treatment duration both predicted
improvement in global psychopathology and disorganized symptoms independent of age, sex, ethnicity, sub-
stance use, co-medication with antidepressants and/or anticholinergics, as well as the dose and duration of anti-
psychotic exposure.
Conclusions:Our findings suggest that the relationship between treatment-emergent weight gain and psychopa-
thology improvement is not limited to patients treated with antipsychotics most associated with weight gain,
and is not confounded by treatment duration and dose.









An increased prevalence of weight gain and metabolic syndrome in
schizophrenia spectrum disorders contributes to elevated risk for car-
diovascular disease (CVD) which is associated with excess morbidity
and mortality (Riordan et al., 2011). In addition to diet, lifestyle and ge-
netic factors, antipsychotic use has emerged as a major contributor to
the higher risk for treatment-emergent metabolic syndrome evident
for schizophrenia (Saha et al., 2007; Emul and Kalelioglu, 2015) even
in first-episode cases (Tek et al., 2016). The high obesogenic potential
of several second-generation antipsychotics is well known, with these
drugs also posing an independent risk for metabolic changes associated
with obesity (Falissard et al., 2011; Leucht et al., 2013). A recent meta-
analysis (Bak et al., 2014) confirms that these changes are not limited
to the second-generation antipsychotics and that almost all antipsy-
chotics are associatedwithweight gain given sufficient treatment expo-
sure. Indeed, certain metabolic abnormalities including hypertension
may bemore pronounced in patients treated with first-generation anti-
psychotics (Falissard et al., 2011), underscoring the need for early as-
sessment and monitoring of cardio-metabolic risk in first-episode
schizophrenia irrespective of antipsychotic type.
Several early studies dated prior to the introduction of second-
generation antipsychotics (Planansky, 1958; Klett and Caffey Jr, 1960)
suggested the prognostic importance of weight gain as a marker of
favourable treatment outcome. Multiple subsequent studies have also
reported that weight gain is associated with decreased global and
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general psychopathology in adult schizophrenia spectrum disorder pa-
tients, particularly those treated with clozapine and olanzapine
(Sharma et al., 2014). Elevated serum lipids associated with antipsy-
chotic use may also predict psychopathology improvement in acute
and long-term settings (Lally et al., 2013; Solberg et al., 2015, 2016). Fi-
nally, greater reduction in global psychopathology has been correlated
with weight gain (Kemp et al., 2013) and metabolic syndrome
(Grover et al., 2016) in adolescent schizophrenia patients. A recent sys-
tematic review reported a link between antipsychotic-induced weight
gain and therapeutic benefit in 22 (71%) of the 31 independent studies
investigated, which collectively included 6063 patients with schizo-
phrenia and related severe mental illnesses (Raben et al., 2018). These
findings are in accordance with those reported in a previous review by
Sharma et al. (2014) which reported an association between
treatment-emergent metabolic changes and antipsychotic efficacy in
14 of the 15 studies evaluated. These systematic review findings sup-
port a relationship betweenweight gain and psychopathology improve-
ment in schizophrenia patients independent of age, sex, ethnicity and
prior antipsychotic use. The findings also raise the possibility of a poten-
tial shared mechanistic pathway between metabolic changes induced
by weight gain and antipsychotic efficacy (Venkatasubramanian et al.,
2013).
However, the relationship ofmetabolic syndrome to disease severity
and clinical outcome remains incompletely described (Blin andMicallef,
2001). Several studies have failed to replicate a correlation between
antipsychotic-induced weight gain and psychopathology improvement
(Umbricht et al., 1994; Hummer et al., 1995). Further, themajority of re-
ported associations of weight gain to date have been with global and
general psychopathology, while mixed results were reported for posi-
tive and negative symptoms (Czobor et al., 2002; Procyshyn et al.,
2007), and the illness-specificity of these findings has been questioned.
In addition, the causal basis for such a relationship remains unclear, as
reports of an association between weight loss and exacerbation of psy-
chosis are conflicting (Chen et al., 2014; Chukhin et al., 2016). In addi-
tion, it remains unclear whether switching to antipsychotics with a
lower obesogenic potential influences the effect of weight gain on treat-
ment outcomes. Outcome studies to date are further limited by impor-
tant confounders including variable treatment end-points and
inconsistent approaches to dealing with dropouts, non-standardised
antipsychotic treatment of patients, not assessing the role of adherence,
and including chronic schizophrenia samples where previous medica-
tion and illness chronicity may affect outcome (Raben et al., 2018).
Lastly, the potential modulating effects of add-on treatment such as an-
tidepressants (Terevnikov et al., 2013; Lu et al., 2017) have not been ex-
tensively considered.
There is a critical lack of evidence from prospective longitudinal
studies assessing the relationships between treatment-emergent
weight gain/metabolic changes and treatment response in patients
treatedwith antipsychotics other than themore commonly studied sec-
ond generation drugs clozapine and olanzapine represented in most in-
vestigations to date. Importantly, most studies to date have also failed to
control for adherence and compliance in a systematic fashion, in addi-
tion to limiting investigation to the acute stage of treatment, typically
less than six months duration (Raben et al., 2018). It is also not always
clear whether duration of treatment exposure has been considered.
However, it stands to reason that patientswith greater antipsychotic ex-
posure are likely to gain more weight, and at the same time show
greater reduction of symptoms. In addition, with the exception of lim-
ited early studies of schizophrenia patients treated with haloperidol
(Bustillo et al., 1996), no studies have explored the link betweenweight
gain and psychopathology improvement in first-episode patients
treated with relatively “weight-neutral” (e.g. aripiprazole, ziprasidone)
or depot (e.g. flupenthixol decanoate) antipsychotics. To the best of our
knowledge, no outcome studies have further sought to evaluate the re-
lationships with particular symptom domains consistently identified
using factor analyses (Emsley et al., 2003; Jerrell and Hrisko, 2013).
In a previous study (Chiliza et al., 2015), we used linearmixed effects
for continuous repeated measures (MMRM) to demonstrate a signifi-
cant visit-wise increase in body mass index (BMI) in antipsychotic-
naïve or minimally treated first-episode schizophrenia patients (n =
107) over 12 months of standardised treatment with flupenthixol
decanoate, independent of age, sex, and end-point antipsychotic dose.
In the present study, we sought to build on these existing findings by
evaluating the relationships between treatment-emergent weight
gain, metabolic changes and psychopathology improvement, drawing
from the abovementioned patient cohort. In this context, we focused
on linear regression analysis selected as themost appropriate statistical
approach to establishing the effects of metabolic change scores as pre-
dictors of change in psychopathology over the course of antipsychotic
treatment in relation to socio-demographic, clinical and treatment-
related covariates.
2. Materials and methods
2.1. Study design and ethics approval
This was a single-site longitudinal study which recruited
antipsychotic-naïve or minimally treated patients with first-episode
schizophrenia spectrum disorders (schizophrenia, schizophreniform
or schizoaffective disorder). Ethical approval was obtained from the
Health and Research Ethics Committee (HREC) at Stellenbosch Univer-
sity (SU) (N06/08/148). Written, informed consent was obtained from
participants and where appropriate, from a legal guardian. Our study
was conducted in accordancewith the International Conference onHar-
monization Good Clinical Practice guidelines (International Conference
on Harmonization, 1996).
2.2. Selection of study participants
Study participants were selected, as part of an ongoing study, from
first admissions to hospitals and community clinics in the metro and
rural areas of North Eastern Cape Town, the Winelands and the West
Coast over a four year period (2007–2011). Inclusion criteria were
men and women, in- or out- patients, aged 18 to 45 years, with a first
psychotic episode meeting Diagnostic and Statistical Manual of Mental
Diseases, Fourth Edition, Text Revisions (DSM-IV TR) (American Psychi-
atric Association, 1994) criteria for schizophrenia, schizophreniform or
schizoaffective disorder. Exclusion criteria were: lifetime exposure to
N4 weeks of antipsychotic medication, serious or unstable medical con-
dition, psychosis arising from acute substance intoxication, and intellec-
tual disability.
2.3. Antipsychotic treatment
Patientswere treated according to a fixed protocol with flupenthixol
decanoate. First-choice treatmentwith a depot antipsychotic was based
on evidence that their greatest benefits may be observed early in the ill-
ness by improving adherence and preventing accruing morbidity, as
well as their demonstrated efficacy and tolerability in this population
(Chue and Emsley, 2007). We chose flupenthixol decanoate as the
best-tolerated depot that was available in the public sector in South
Africa. There was a seven-day lead-in with oral flupenthixol
1–3 mg/day followed by flexible doses of flupenthixol decanoate. The
starting dose was 10 mg IM 2-weekly. The lowest possible dose was
maintained, and only increasedwhen an insufficient response persisted.
Additional oral flupenthixol was permitted, but seldom prescribed. Per-
mitted concomitant medications included lorazepam, biperidin,
orphenadrine, propranolol and antidepressants. In order to minimize
the potential effects of additional treatment onmetabolic status, benzo-
diazepines, anticholinergics and propranolol were not allowed within
12 h of the time of assessment. Prohibited medications included other
antipsychotics, mood stabilizers and psychostimulants.
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2.3.1. Clinical assessments
Patients were assessed with the Structured Clinical Interview for
DSM-IV (SCID) (First et al., 1994) and psychopathology was assessed
by the Positive and Negative Syndrome Scale (PANSS) (Kay et al.,
1987). Evaluation of psychopathology symptom categories was per-
formed by calculating PANSS factor analysis-derived domains (i.e. posi-
tive, negative, depressive-anxiety, disorganized and exhibition-hostility
symptoms) (Emsley et al., 2003). Remission status was also assessed
using the Remission in Schizophrenia Working Group (RSWG) consen-
sus criteria proposed by Andreasen et al. (2005).
2.3.2. Metabolic assessments
A physical examination was performed at baseline and study com-
pletion. Body weight was measured at baseline, week 6, and months
3, 6, 9 and 12. Patients removed all surplus clothing including their
socks and shoes and were weighed on an electronic scale that was reg-
ularly calibrated throughout the study. Height was measured with a
pre-fixed wall-mounted measuring tape. Body mass index (BMI) was
also calculated as the patient's body weight in kilograms (kg) divided
by their height in meters squared (m2). While we also measured waist
circumference, we did not use this in the analyses, due to a large num-
ber of missing values (n = 26, 25%). Systolic (SBP) and diastolic (DBP)
blood pressures were assessed at baseline and at months 3, 6 and 12.
A peripheral venous blood sample was collected from participants fol-
lowing an eight hour fasting period and ten minute rest prior to
venepuncture. Biochemical testing was performed at baseline and
again at months 3, 6, 9 and 12, and included assessment of the fasting
lipid profile (triglycerides, total, LDL and HDL cholesterol) and glucose
levels.
2.3.3. Urine toxicology
Urine toxicologywas performed at baseline and again atmonths 3, 6
and 12 to assess use of cannabis, methaqualone andmethamphetamine
over the course of the study. Patients who tested positive on any occa-
sion were classified as substance use positive.
2.4. Statistical analysis
Statistical analyses were performed using the R Studio software
package. All participants with at least one baseline and one follow-up
measure were included for analysis. End-point scores were calculated
by last observation carried forward. Clinical and metabolic change
scores were calculated by subtracting the baseline score from the end-
point score. Descriptive statistics and graphical summaries were used
to assess whether the key variables meet standard assumptions for
the planned analyses and to identify outliers. Non-normal data was
log-transformed prior to analysis. Categorical variables were described
using cross-tabulation and frequency tables and compared between
study groups using the Pearson's Chi-Squared or Fisher's exact tests.
Normality of distribution for numerical variables was established
using the Shapiro-Wilk test. For normally distributed data, quantitative
phenotypeswere described as themeans alongwith standard deviation
(SD) and compared between study groups using a Student's t-test. Lin-
ear correlations were described using the Pearson's correlation or
Spearman's rank correlation as applicable. Post-hoc Bonferroni correc-
tions were performed where applicable to correct for multiple compar-
isons across the six psychopathology domains of interest (i.e. PANSS
total score as well as positive, negative, disorganized, depressive-
anxiety and excitement-hostility domains). Linear regression models
were constructed to evaluate the role ofmetabolic change scores as pre-
dictors of psychopathology improvement in relation to socio-
demographic (age, sex, ethnicity), clinical (substance use) and
treatment-related (antipsychotic dose, treatment duration, antidepres-
sant and/or anticholinergic co-medication)variables.
3. Results
3.1. Baseline characteristics of study population
Our study included 106 antipsychotic-naïve or minimally treated
first-episode schizophrenia spectrumdisorder patients (77males, 29 fe-
males; mean age= 24.2 years). In total, 79 patients had a DSM-IV diag-
nosis of schizophrenia, while 26 patients were diagnosed with
schizophreniform disorder, and one patient with schizoaffective disor-
der. Forty-one (39%) patients had a family history of schizophrenia.
Mean duration of untreated psychosis (DUP) for the total sample was
34 weeks. Our sample consisted of self-reported Mixed Ancestry (n =
81, 76%), as well as Caucasian (n = 15, 14%) and Black African (n =
10, 9%) patients. The distribution of male to female patients was repre-
sentative of that observed in our larger study sample (Chiliza et al.,
2015) and reflects the sex distribution of patients presenting to the
health care services in our catchment area. The 2-weeklymean modal
dose of depot flupenthixol decanoate was 10 mg in the majority (n =
67; 63%) of patients, 15 mg in 15 (14%) patients, 20 mg in 12 (11%) pa-
tients, 5 mg in five (5%)patients, and 20mg in one (1%) patient. In addi-
tion, 29 (27%) patients used benzodiazepines and three (3%)
propranolol as needed over the course of the study, while 17 (16%)
were prescribed anticholinergic drugs, and nine (8%) antidepressants.
In total, 22 (21%) patients received antidepressant and/or anticholiner-
gic co-medication, which were considered of interest as a treatment-
related confounder due to their known association with weight gain
and associated metabolic syndrome changes. A total of 64 (60%) pa-
tients completed the month 12 assessment; 98 (92%) patients had a
treatment period of at least sixmonths necessary to assess symptomatic
remission status according to the RSWG criteria,with 63 (64%) attaining
symptomatic remission.
A comparison of the baseline and end-point values for clinical and
metabolic parameters is presented in Table 1. There was a significant
decrease in PANSS total score as well as all factor-derived domains
(i.e. positive, negative, disorganized, depressive-anxiety and
excitement-hostility symptoms) from baseline to end-point (all p b
0.001). Mean BMI (p b 0.001) and triglycerides (p b 0.001) significantly
increased, while HDL cholesterol significantly decreased (p = 0.001)
from baseline to end-point. SBP, DBP and glucose did not change signif-
icantly from baseline to end-point. Visit-wise changes in BMI over the
course of antipsychotic treatment in relation age, sex and end-point
Table 1











PANSS total score 94.64 (15.90) 48.16 (13.48) b0.001
PANSS positive symptoms 17.36 (3.26) 6.06 (3.10) b0.001
PANSS negative symptoms 20.14 (5.41) 11.52 (4.62) b0.001
PANSS disorganized symptoms 11.98 (2.90) 6.48 (2.39) b0.001
PANSS depressive-Anxiety
symptoms
9.08 (4.25) 5.39 (2.48) b0.001
PANSS excitement-hostility
symptoms
8.29 (3.84) 4.71 (1.64) b0.001
Metabolic
Body mass index (kg/m2) 21.68 (3.87) 24.38 (4.97) b0.001





Diastolic BP (mmHg) 79.54 (10.34) 79.91 (10.18) 0.794
Glucose (mmol/L) 4.78 (0.71) 4.97 (1.37) 0.205
HDL cholesterol (mmol/L) 1.17 (0.55) 0.98 (0.26) 0.001
Triglycerides (mmol/L) 0.88 (0.52) 1.22 (0.85) b0.001
PANSS = Positive and Negative Symptom Scale; BP = blood pressure; HDL = high-den-
sity lipoprotein.
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flupenthixol dose were previously described in our study cohort (see
Chiliza et al., 2015).
3.2. Relationship between weight loss and psychopathology change scores
A total of 20 (19%) patients lost weight over the course of our study;
no significant differences in clinical change scores were noted between
this subgroup and the rest of the study population (p N 0.05).
3.3. Relationship between metabolic change scores and treatment
characteristics
DUP,modal antipsychotic dose and treatment durationwere not sig-
nificantly associatedwith any of themetabolic change scores of interest
(p N 0.05). Weight gain and associated metabolic change scores were
compared between remitters (n = 63) and non-remitters (n = 35) in
a subgroup of 98 patients for whom sustained symptomatic remission
could be assessed. No significant differences in change scores for BMI,
SBP, DBP, glucose, triglycerides or HDL cholesterol were noted between
remitters and non-remitters.
3.4. Correlation between baseline psychopathology and metabolic
characteristics
In the total study group, triglyceride levels were negatively corre-
lated with disorganized symptom severity at baseline (r = −0.29, p
= 0.002). This correlation retained significance following post-hoc
Bonferroni correction (0.008). A trend was also noted for an inverse as-
sociation between triglycerides and total PANSS score at baseline (r =
−0.16, p = 0.065). BMI, glucose and HDL cholesterol were not signifi-
cantly correlated with total PANSS score or any specific symptom do-
main at baseline (Table 2).
3.5. Correlations between psychopathology improvement and metabolic
change scores
BMI change scores were inversely correlated with change in PANSS
total (r = −0.25; p = 0.011) as well as positive (r = −0.23; p =
0.019), depressive-anxiety (r = −0.21; p = 0.031) and disorganized
symptoms (r = −0.32; p b 0.001) but not negative or excitement-
hostility symptoms (p N 0.05). The inverse correlation between BMI
and disorganized symptom change scores (Fig. 1) survived Bonferroni
correction (0.008). Change in fasting glucose was inversely correlated
with change in positive symptoms (r = −0.21; p = 0.034), while
change in triglycerideswas inversely associatedwith change in disorga-
nized symptoms (r = −0.20; p = 0.040). SBP, DBP and HDL change
scores were not significantly related to improvement in global psycho-
pathology or factor-derived symptom domains (Table 3).
3.6. Metabolic factors as predictors of psychopathology improvement
Separate linear regression models were constructed with change
scores for global psychopathology (model 1) and the domains of
disorganized (model 2), positive (model 3) and depressive-anxiety
(model 4) symptoms as dependent variables, selected based on their
significant correlations with metabolic parameter change scores on ini-
tial analysis.We entered BMI andmetabolic change scores as predictors
and socio-demographic (age, sex, ethnicity), clinical (substance use) as
well as treatment-related (antipsychotic dose, treatment duration, co-
medication with antidepressants and/or anticholinergics) factors as co-
variates. In model 1 (R2 = 0.26, F(14,89) = 2.29, p = 0.010), BMI
change scores (β = −1.25, p = 0.061) and treatment duration (β =
−0.72, p b 0.001) were independent predictors of the variance in
PANSS total symptoms. In model 2 (R2 = 0.28, F(14,89) = 2.50, p =
0.005), BMI change scores (β=−0.29, p= 0.004) and treatment dura-
tion (β=−0.09, p= 0.002) were also significant predictors of the var-
iance in PANSS disorganized symptoms. In model 3, (R2 = 0.30, F
(14,89) = 2.73, p = 0.002), only treatment duration (β = −0.16, p b
0.001) was a significant predictor of the variance in positive symptoms.
Model 4 was not significant for improvement in depressive-anxiety
symptoms (R2 = 0.17, F(14,89) = 1.27, p = 0.241).
4. Discussion
Themain finding from the present studywas that increased BMI sig-
nificantly correlated with improved global psychopathology and the
disorganized symptoms of schizophrenia over thefirst 12months of an-
tipsychotic treatment. This association remained significant after con-
trolling for the effects of age, sex, ethnicity, substance use, co-
medication with antidepressants and/or anticholinergics, as well as
the dose and duration of antipsychotic exposure. These findings are in
accordance with those reported in previous studies suggesting a link
Table 2
Results from correlation analysis evaluating the linear relationship between clinical symptoms and metabolic parameters at baseline, presented as the R-value and corresponding unad-
justed p-values.








BMI (kg/m2) baseline −0.11; 0.265 0.04; 0.650 −0.07; 0.487 −0.12; 0.219 −0.05; 0.646 −0.03; 0.778
SBP (mmHg) baseline −0.04; 0.659 −0.10; 0.305 0.04; 0.661 0.06; 0.565 −0.07; 0.474 −0.11; 0.253
DBP (mmHg) baseline −0.04; 0.685 −0.04; 0.719 0.07; 0.464 −0.09; 0.381 0.04; 0.713 −0.10; 0.291
Glucose (mmol/L) baseline −0.04; 0.648 0.01; 0.916 −0.02; 0.869 −0.13; 0.182 −0.08; 0.410 0.05; 0.609
HDL cholesterol (mmol/L) baseline −0.01; 0.936 0.05; 0.633 0.06; 0.523 −0.06; 0.565 0.04; 0.710 −0.14; 0.157
Triglycerides (mmol/L) baseline −0.16, 0.065 −0.01; 0.912 −0.14; 0.153 −0.29; 0.002 0.01; 0.903 −0.09; 0.375
PANSS = Positive and Negative Symptom Scale; BP = blood pressure; HDL = high-density lipoprotein.
Fig. 1. Scatterplot diagram illustrating a significant inverse association between change
scores for body mass index (BMI) and the disorganized symptom domain.
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between treatment-emergent weight gain and therapeutic response in
schizophrenia spectrum disorder patients (Sharma et al., 2014; Raben
et al., 2018).
Importantly, our results extend previous research insofar aswewere
able to exclude several important factors that may have confounded
these findings. First, we were able to control precisely for dose and du-
ration of antipsychotic exposure. Similarly, poor adherence is likely as-
sociated with both worse outcome and reduced obesogenic effect of
antipsychotics. Our use of depot formulation antipsychotic provided as-
sured delivery and removed the confounding effect of non-adherence.
Thismay be important, given the very high rates non- and partial adher-
ence reported in the early stages of illness (Coldham et al., 2002). Addi-
tionally, by including only first-episode and minimally treated or never
treated patients, we removed the effects of illness chronicity and previ-
ous medication. Finally, by standardising treatment with a single anti-
psychotic we addressed the potential confound of differential
treatment effects in terms of both efficacy and weight gain. To the
best of our knowledge, this is the first study to report an independent
effect of weight gain on improvement in disorganized symptoms in a
sample treatment-naïve or minimally treated patients with schizophre-
nia spectrum disorder. Most previous studies reporting a relationship
between metabolic side effects and clinical improvement were con-
ducted in chronic samples. Also, most studies investigated patients
treated with clozapine and olanzapine - the two antipsychotics associ-
ated with the greatest risk of weight gain - with other drugs being
poorly represented (Sharma et al., 2014).
Our results suggest that the relationship is not restricted to these
two drugs, andmay be present evenwith antipsychotics less frequently
associated with weight gain. Indeed, flupenthixol is considered to be
relatively “weight neutral” (Messer et al., 2009), although first-
episode patients are more susceptible and significant weight gain has
been reported in these patients (Chiliza et al., 2015). Whether weight
gain is a necessary concomitant of efficacy (Sharma et al., 2014) remains
to be further elucidated, although our results suggest that this is not the
case, as the 20 patients who lost weight in our study did not do signifi-
cantly worse than the rest of the sample.
There are several possible explanations for the link between weight
gain and favourable treatment response. Firstly, it may be that greater
improvement in symptoms leads to better and more structured
health-seeking behaviours, including proper self-care and healthier
diet. In this respect, our finding of an association between weight gain
and improvement in disorganized symptoms specifically, may be rele-
vant. Disorganized symptoms are a major contributor to acute impair-
ment in functioning (Ortiz et al., 2017), health and wellbeing (Javitt,
2015). A secondpossibility is that the effects of antipsychotics on neuro-
transmitters that are responsible for weight gain may, at least in part,
also be responsible for the efficacy of these agents (Meltzer et al.,
2003). In particular, serotonin signalling may play a role, given its in-
volvement in the regulation of appetite and satiety, with 5HT2C recep-
tor blockade being directly implicated in antipsychotic-associated
weight gain (Reynolds et al., 2006; Panariello et al., 2011), as well as
its association with clinical response in schizophrenia (Gressier et al.,
2016). Unlike most conventional antipsychotics, flupenthixol is a
5HT2A and 5HT2C receptor blocker (Wiesbeck et al., 2003). The role
of the orexin hypothalamic neuropeptidesmay also be relevant. Orexins
play a role in appetite regulation and energy homeostasis (Panariello
et al., 2011) and share interaction mechanisms with serotonin
(Donovan and Tecott, 2013). In this context, and of relevance to our
findings, Chien et al. (2015) recently reported a correlation between
lower disorganized and negative symptom severity and higher orexin
A levels in a study of 127 schizophrenia patients, implicating orexin in
treatment response.
Several recent studies have reported that elevated lipidsmay predict
clinical response in schizophrenia (Solberg et al., 2015, 2016). Our re-
sults in this regardwere less clear-cut. Thus, whilewe found several sig-
nificant correlations between treatment-emergent metabolic changes
other thanweight gain and a decrease in specific factor-derived domain
scores in the bivariate correlational analyses, none of these associations
remained significant in the regressionmodels. Nevertheless, our finding
of an association between baseline triglycerides and PANSS total symp-
tom severity, and increased triglycerides and greater reductions in dis-
organized symptoms, is consistent with previous work reporting an
association between elevated triglycerides and fewer negative symp-
toms (Procyshyn et al., 2007; Lally et al., 2013), which share a strong as-
sociation with disorganized symptoms (Demjaha et al., 2012). An
association between increased lipids and better treatment response
could be explained by lipid partitioning and altered blood-brain barrier
permeability affecting antipsychotic levels, although elevated triglycer-
idesmay also exert a favourable effect on central serotonin transmission
(Dursun et al., 1999) and perhaps also reflect a favourable change in
central lipid metabolism and myelination potential or efficacy (Chrast
et al., 2011). Finally, the inverse correlation between glucose and posi-
tive symptom change scores that we found is consistent with the pro-
posal that insulin signalling is the common pathway linking metabolic
risk with therapeutic benefit (Girgis et al., 2008).
The strengths of this study lie in its longitudinal design and evalua-
tion of a well-characterized cohort of first-episode, minimally treated
patients. Also, regular clinical and laboratory assessments allowed for
accurate evaluation of changes over time. In addition, standardised
treatment with a single antipsychotic ruled out the differential effects
of treatment. However, there are important limitations. First, a longer
treatment period would have been preferable and may have more
clearly identified relationships between lipid and glucose changes and
treatment outcome. Second, our sample was drawn from a largely
socio-economically deprived community with low baseline BMI.
Thirdly, our study did not include the assessment of waist circumfer-
ence as an indicator of central obesity, and dietary habits and physical
activity as determinants of cardio-metabolic risk in schizophrenia spec-
trum disorder patients treated with antipsychotics were not examined.
Finally, our study only included patients treated with flupenthixol
decanoate. These limitations mean that our findings are not necessarily
generalizable to other patient populations which may differ in terms of
clinical profile, treatment approach and metabolic risk profile.
In conclusion, our study supports the notion that weight gain is re-
lated to antipsychotic efficacy, perhaps via shared mechanistic path-
ways. The possible clinical usefulness of assessment and monitoring of
metabolic syndrome risk in predicting treatment outcome remains to
be defined.
Table 3
Results from correlation analysis evaluating the linear relationship between clinical and metabolic change scores, presented as the R-value and corresponding unadjusted p-values.
PANSS total change Positive change Negative change Disorganized change Depressive-anxiety change Excitement-hostility change
BMI (kg/m2) change −0,25; 0.011 −0.23; 0.019 −0.09; 0.364 −0.32; b0.001 −0.21; 0.031 −0.02; 0.866
SBP (mmHg) change 0.06; 0.524 b−0.01; 0.973 0.07; 0.507 0.05; 0.594 0.06; 0.538 −0.02; 0.868
DBP (mmHg) change b−0.01; 0.925 b0.01; 0.926 0.06; 0.570 0.01; 0.934 0.06; 0.539 −0.12; 0.240
Glucose (mmol/L) change −0.06; 0.513 −0.21; 0.034 0.11; 0.256 −0.01; 0.935 0.02; 0.874 −0.04; 0.717
HDL cholesterol (mmol/L) change b0.01; 0.978 0.10; 0.308 0.02; 0.832 −0.04; 0.674 −0.06; 0.509 −0.11; 0.268
Triglycerides (mmol/L) change −0.09; 0.341 −0.13; 0.168 −0.13; 0.176 −0.20; 0.040 0.02; 0.846 0.06; 0.550
PANSS = Positive and Negative Symptom Scale; BP = blood pressure; HDL = high-density lipoprotein.
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Abstract
Few studies have investigated the longitudinal effects of treatment-emergent metabolic syndrome changes on cognitive perfor-
mance in first-episode psychosis. The aim of the present study was to determine the associations between changes in metabolic
syndrome constituent component over 12 months of treatment and end-point cognitive performance in schizophrenia spectrum
disorders. This single site-cohort study included 72 minimally treated or antipsychotic-naïve first-episode patients. Cognitive
performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). Our primary objective of interest was
the relationship between metabolic syndrome constituent component changes over 12 months of treatment and end-point
cognitive performance. Secondary objectives included investigating whether this relationship was affected by age, sex, antipsy-
chotic dose, treatment duration and substance use. Weight gain predicted better overall cognition (p = 0.02) at end-point,
adjusting for age, sex, substance use, baseline cognitive score and BMI, modal antipsychotic dose and treatment duration.
Weight loss (p = 0.04) and substance use (p = 0.01) were both associated with poorer working memory performance at end-
point. Low baseline BMI showed differential effects on end-point working memory performance in substance users
(unfavorable) compared to non-users (favorable) (p < 0.05). In conclusion, weight gain over the course of antipsychotic treatment
is associated with better overall cognitive performance and the working memory domain in first-episode schizophrenia spectrum
disorder patients. In contrast, low baseline BMI may represent an unfavorable marker in substance users, who demonstrated
weight loss compared to non-users.
Keywords First-episode schizophrenia spectrum disorders . Cognitive performance .Workingmemory .MCCB .Weight gain
Introduction
In patients with schizophrenia, metabolic syndrome is associ-
ated with cognitive impairments, including executive dys-
function, poor working memory and altered attention/
vigilance (Guo et al. 2013 ; Bora 2016 ). This is important,
given the increased risk for development of metabolic syn-
drome in schizophrenia patients (Mitchell et al. 2013 ).The
impact of metabolic syndrome on cognitive dysfunction is
pronounced in patients with severe negative symptoms, and
increases in parallel with the number of metabolic syndrome
risk factors present (Lindenmayer et al. 2012; Boyer et al.
2013 ; Botis et al. 2016 ; Bora et al. 2017a). Meta-analyses
have further confirmed the effects of metabolic syndrome
and type II diabetes mellitus (DM II) as determinants of poor
overall cognition in schizophrenia (Bora et al. 2017b). Better
cognitive performance at baseline has also been associated
with a favorable metabolic profile at follow-up in schizophre-
nia (Storch-Jakobsen et al. 2018 ).
Individual metabolic syndrome constituent components
may exert distinct effects on specific cognitive domains in
schizophrenia. For example, elevated waist circumference
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has been correlated with decreased motor speed (Botis et al.
2016) and attention/vigilance (Lindenmayer et al. 2012),
while hypertension and elevated triglycerides have been asso-
ciated with poorer verbal memory (Friedman et al. 2010;
Goughari et al. 2015). On the other hand, opposing literature
suggests certain metabolic syndrome features such as hyper-
tension, hyperglycemia and dyslipidaemia may be associated
with better performance in certain cognitive domains affected
in schizophrenia (Goughari et al. 2015; Wysokinski et al.
2013). Interestingly, several prospective studies have reported
that changes in certain metabolic syndrome constituent com-
ponents including elevated lipids predict cognitive improve-
ment in schizophrenia (Krakowski and Czobor 2011;
Nasrallah and Blom 2015). These findings are in keeping with
studies showing an association between high cholesterol
levels and better performance on verbal fluency, reasoning,
motor speed and attention/concentration in population-based
cohorts (Elias et al. 2005).
In contrast to a well-documented association with psycho-
pathology improvement in schizophrenia (Raben et al. 2018),
the relationship between weight gain and cognitive perfor-
mance over the course of antipsychotic exposure remains
poorly described. Indeed, there is a paucity of evidence from
longitudinal studies of well-characterized first-episode pa-
tients investigating the relationship between changes in
antipsychotic-induced metabolic syndrome constituent com-
ponents and cognitive performance in schizophrenia. In re-
sponse to this knowledge gap, the aim of the present study
was to determine the associations between changes in meta-
bolic syndrome constituent component over 12 months of
treatment and end-point cognitive performance in schizophre-
nia spectrum disorders. Our primary objective was to investi-
gate the relationship between change in body mass index
(BMI) over 12 months of treatment and end-point cognitive
performance. Secondary objectives included to determine
whether this relationship is affected by age, sex, antipsychotic
dose, treatment duration and substance use.
Firstly, we hypothesized that increased BMI would be as-
sociated with better overall cognition at end-point, adjusting
for modal antipsychotic dose, treatment duration and sub-
stance use, in accordance with our previous finding that
weight gain predicted global psychopathology improvement
in first-episode patients independent of these covariates
(Luckhoff et al. 2018). Secondly, we anticipated that sub-
stance use would affect the relationship between weight gain
and end-point performance in specific cognitive domains, giv-
en our previous finding that patients who used cannabis, un-
like their non-using counterparts, did not gain significant
weight when treated with antipsychotics (Scheffler et al.
2018). In addition, our focus on working memory in particular
was motivated by its importance in the control of appetite and
weight gain (Higgs and Spetter 2018) as well as recent evi-
dence that ongoing substance use is associated with poorer
working memory performance in first-episode or early psy-
chosis (Bogaty et al. 2018; Sanchez-Gutierrez et al. 2018).
Materials and methods
Study design and ethics approval
The present single-site longitudinal study, which recruitedmin-
imally treated or antipsychotic-naive first-episode schizophre-
nia patients, was conducted as part of a larger parent project
(N06/08/148), with ethical approval obtained from the Health
and Research Ethics Committee (HREC) at Stellenbosch
University (SU). Written, informed consent was obtained from
all participants, and in the case of participants younger than
18 years of age, we obtained written, informed consent from
parents or legal guardians.
Selection of study participants
Study participants were selected from first admissions to hos-
pitals and community clinics in the metro and rural areas of
North Eastern Cape Town, the Winelands and West Coast
over a 4 year period (2007–2011). Inclusion criteria were
men and women, in- or outpatients, aged 18 to 45 years, with
a first psychotic episode meeting Diagnostic and Statistical
Manual of Mental Diseases, Fourth Edition, Text Revisions
(DSM-IV TR) (American Psychiatric Association 1994)
criteria for schizophrenia, schizophreniform or schizoaffective
disorder. Exclusion criteria included lifetime exposure to more
than 4 weeks of antipsychotic medication, serious or unstable
medical condition, and substance-induced psychosis.
Antipsychotic treatment
Patients were treated according to a fixed protocol with
flupenthixol decanoate, a depot antipsychotic. There was a
lead-in period of 7 days with oral flupenthixol 1–3 mg/day
followed by flexible doses of flupenthixol decanoate intra-
muscular injections 2-weekly. Permitted concomitant medica-
tions included lorazepam, anticholinergics, propranolol, anti-
depressants and medications for medical conditions.




Patients were assessed with the Structured Clinical Interview
for DSM-IV (SCID) (First et al. 1994). The MATRICS
Consensus Cognitive Battery (MCCB) was utilized as a tool
specifically designed and validated for the assessment of
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cognitive functioning in schizophrenia (Nuechterlein and
Green 2006). The MCCB comprises seven domains and a
composite score. The individual domains are: 1) speed of
processing, 2) attention/vigilance, 3) working memory, 4)
verbal learning, 5) visual learning, 6) reasoning and problem
solving, and 7) social cognition. The MCCB was adminis-
tered at baseline, month 6 and month 12 by trained psychol-
ogists under supervision of an experienced clinical psychol-
ogist and psychiatrist. The MCCB computer program was
used to transform raw scores into individual domain and
composite T-scores. Age- and sex-corrected norms were used
according to the guidelines outlined in the MCCB manual
(Nuechterlein and Green 2006). We compared metabolic
syndrome constituent component change scores with
MCCB end-point scores rather than the MCCB change
scores, as the baseline cognitive tests were performed while
patients were acutely psychotic and this may have confound-
ed the scores. The end-point MCCB scores therefore
assessed cognitive performance in clinically stable patients.
Metabolic assessments
A physical examination was performed at baseline, follow-up
and study completion. Body weight was measured at baseline
and months 3, 6, 9 and 12. Study participants removed all
surplus clothing including socks and shoes and were weighed
on an electronic scale calibrated throughout the study. Height
was measured using a pre-fixed wall-mounted measuring
tape.BMI was also calculated as the patient’s body weight in
kilograms (kg) divided by their height in meters squared (m2).
Clinically significant weight gain was defined as >7% in-
crease in body weight from baseline to end-point (McIntyre
et al. 2003). A peripheral venous blood sample was collected
from participants following an 8 hour fasting period and 10
minute rest prior to venepuncture. Biochemical testing was
performed at baseline and again at months 3, 6, 9 and 12,
and included assessment of the fasting lipid profile (triglycer-
ides, total, LDL and HDL cholesterol) and glucose levels.
Urine toxicology
Urine toxicology was performed at baseline and again at
months 3, 6 and 12 to assess use of cannabis, methaqualone
and methamphetamine over the course of the study. Patients
who tested positive were classified as substance use positive.
Statistical analysis
Statistical analyses were performed using the R Studio soft-
ware package (version 3.2.4) and confirmed by a biostatisti-
cian using the IBM SPSS software program (version 25). All
participants with at least one baseline and one follow-up
measure were included for analysis. End-point scores were
calculated by last observation carried forward, and metabolic
change scores were calculated by subtracting the baseline
score from the end-point score. Categorical characteristics
were described using cross-tabulation and frequency tables
and compared between study groups using the Pearson’s
Chi-Squared or Fisher’s exact tests. For normally distributed
data, quantitative phenotypes are given as means and the
standard deviation (SD). Linear correlations between meta-
bolic change scores and MCCB end-point scores were de-
scribed using Pearson’s correlation analysis. Winsorized data
were utilized for triglyceride and HDL cholesterol change
scores in order to minimize the potential effects of outliers,
and a significance level of p < 0.10 was used to identify
predictor variables for subsequent linear regression analyses.
In all other analyses, statistical significance was defined as a
p value <0.05.
Results
Characteristics of study population
From an initial group of 126 patients, we included 72 largely
treatment-naive, first-episode schizophrenia spectrum disor-
der patients (53 males, 19 females; mean age = 24.2 years)
for whom sufficient data were available to calculate metabolic
syndrome constituent component change scores (baseline and
at least one follow-up visit) as well as composite MCCB score
at end-point. In total, 57 patients (79%) had a DSM-IV diag-
nosis of schizophrenia, while 15 patients (21%) were diag-
nosed with schizophreniform disorder. The sample consisted
mostly (n = 53; 74%) of patients of Mixed Ancestry, and fur-
ther included 11 Caucasian (15%) and eight Black African
(11%) patients. The majority of males tested positive for use
of illicit substances (n = 31, 58%) compared to a minority (n =
4, 21%) of females. In total, 35 patients (49%) tested positive
for substance use, of which 28 (80%) were positive for can-
nabis use. Modal 2-weekly dose of depot flupenthixol
decanoate was 10 mg in 47 (65%) patients, 15 mg in 15
(21%) patients, 20 mg in seven (10%) patients, and 5 mg in
three (4%) patients.
The baseline and end-point scores for the cognitive and
metabolic outcomes of interest are presented and compared
in Table 1. There was a significant increase in MCCB com-
posite score (p = 0.04) as well as the attention/vigilance
(p < 0.01) and reasoning/problem-solving domains (p = 0.01)
from baseline to end-point. In addition, a significant increase
in mean BMI (p < 0.01) and triglycerides (p < 0.01) as well as
a decrease in HDL cholesterol (p < 0.01) was noted from base-
line to end-point. Glucose (p = 0.18), total cholesterol (p =
0.39) and LDL cholesterol (p = 0.30) did not change signifi-
cantly over the course of the study.
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Effects of baseline BMI and weight change
on end-point cognitive scores
Baseline BMI was not associated with the composite MCCB
score or any specific cognitive domains at end-point
(p > 0.05). A total of 45 patients (63%) experienced clinically
significant weight gain, which was not significantly associated
with the composite MCCB end-point score or any of the spe-
cific cognitive domains at end-point (p > 0.05). In total, 14
patients (19%) lost weight over the course of the present study.
These patients had poorer end-point working memory scores
(mean = 25.43) compared to the rest of the patient group
(mean = 32.98) (p = 0.04). Weight loss was not significantly
associated with poorer cognitive performance at end-point for
the composite MCCB score or other specific domains
(p > 0.05).
Correlations between metabolic syndrome change
scores and end-point cognitive scores
Pearson correlation coefficients were calculated to assess the
linear relationship between 1) the composite MCCB score/
specific cognitive domains at end-point, and 2) metabolic
change scores where a significant increase (i.e. BMI, triglyc-
erides) or decrease (i.e. HDL cholesterol) was noted from
baseline to end-point, as shown in Table 2. BMI change scores
were significantly positively correlated with the MCCBwork-
ing memory domain at end-point (r = 0.28; p = 0.02). A sim-
ilar trend was noted towards a positive association between
BMI change scores and the composite MCCB score at end-
point (r = 0.20, p = 0.09). In addition, HDL change scores
were inversely associated with the reasoning/problem solving
domain (r = −0.23; p = 0.05) at end-point, although this
Table 1 Comparison of baseline
and end-point scores for cognitive
performance and metabolic status
for total study group, provided
along with corresponding unad-
justed p values







MCCB Composite score 21.06 (13.33) 26.40 (14.43) 0.04**
MCCB Working memory 27.91 (12.40) 31.51 (12.34) 0.11
MCCB Speed of processing 23.22 (11.11) 27.27 (13.20) 0.07
MCCB Reasoning/problem solving 32.81 (9.25) 37.40 (10.41) <0.01**
MCCB Attention/vigilance 24.64 (11.64) 31.86 (9.93) <0.01**
MCCB Visual learning 31.96 (13.51) 36.49 (12.90) 0.06
MCCB Verbal learning 33.61 (8.52) 34.36 (7.78) 0.61
MCCB Social cognition 46.25 (15.22) 49.57 (18.96) 0.28
Body mass index (kg/m2) 21.72 (4.18) 24.66 (5.36) <0.01**
Glucose (mmol/L) 4.81 (0.76) 5.10 (1.61) 0.18
HDL cholesterol (mmol/L) 1.16 (0.51) 0.96 (0.25) <0.01**
Triglycerides (mmol/L) 0.85 (0.41) 1.22 (0.84) <0.01**
Total cholesterol (mmol/L) 4.22 (1.06) 4.36 (0.87) 0.39
LDL cholesterol (mmol/L) 2.71 (0.89) 2.85 (0.82) 0.30
HDL high-density lipoprotein, LDL low-density lipoprotein,MCCBMATRICS Consensus Cognitive Battery, **
statistically significant
Table 2 Results from correlation analysis evaluating the linear relationship between metabolic change scores andMCCB composite score and specific



















0.20; 0.09 0.28; 0.02 0.19; 0.12 0.02; 0.89 0.07; 0.56 0.10; 0.40 0.16; 0.19 0.17; 0.16
HDL cholesterol change
score (mmol/L)
−0.19; 0.12 −0.15; 0.22 −0.14; 0.25 −0.23; 0.05 −0.07; 0.53 −0.07; 0.57 −0.19; 0.10 −0.14; 0.25
Triglycerides change
score (mmol/L)
0.08; 0.52 0.02; 0.86 −0.02; 0.86 0.07; 0.54 −0.03; 0.81 0.12; 0.31 0.05; 0.69 0.12; 0.31
Predictor variables were identified using a significance level of p < 0.10
AV attention/vigilance, BMI body mass index, HDL high-density lipoprotein,MCCBMATRICS Consensus Cognitive Battery, RPS reasoning/problem
solving, SC social cognition, SOP speed of processing, VERBL verbal learning, VISL visual learning, WM working memory
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correlation did not remain significant when outliers (n = 3)
were removed (r = −0.12, p = 0.33). Based on results from
initial exploratory correlation analyses, we therefore identified
the composite MCCB end-point and working memory do-
main as our dependent variables of interest, and the BMI
change score as our metabolic predictor of interest.
Linear regression analyses
Linear regression models were constructed to assess the rela-
tionship between BMI change scores and the compositeMCCB
score as well as working memory domain at end-point, incor-
porating clinical (age, sex, substance use, baseline cognitive
score and BMI) and treatment-related (modal antipsychotic
dose, treatment duration) factors as covariates (Table 3).
Increase in BMI (β = 1.17, p = 0.02) significantly predicted a
higher composite MCCB score at end-point, adjusting for age,
sex, substance use, modal antipsychotic dose, treatment dura-
tion, baseline composite score and BMI as covariates. In addi-
tion, weight gain (β = 0.89, p = 0.02) predicted better working
memory performance at end-point, adjusting for age, sex, mod-
al antipsychotic dose, treatment duration, baseline composite
score and BMI as covariates (Table 3). The effect of increased
BMI as a predictor of end-point working memory performance
was however non-significant (β = 0.63, p = 0.13) when sub-
stance use was also incorporated into a linear model
(R2 = .58, F(8,46) = 8.24, p < 0.01) adjusting for the same co-
variates (i.e. age, sex, modal antipsychotic dose, treatment du-
ration, baseline composite score and BMI). We therefore per-
formed subsequent sub-analyses to further explore the effects of
substance use on inter-relationship between baseline BMI,
weight gain and end-point working memory performance.
Effects of substance use on baseline BMI, weight
change and working memory performance
Substance use was associated with poorer working memory
scores at end-point (p = 0.01), with a significant improvement
in performance from baseline to end-point only evident for
non-users (p = 0.02). In addition, the majority (n = 11; 78%)
of patients who lost weight (n = 14), which was itself associ-
ated with lower end-point working memory scores (p = 0.04),
tested positive for substance use over the course of the study.
Moreover, a significant increase in BMI over the course of the
study was evident for non-users (p < 0.01) but not substance
users (p > 0.05). Baseline BMI was also significantly lower in
substance users compared to non-users (p = 0.03). Lastly, low
baseline BMI (β = −0.86, p = 0.01) predicted better end-point
Table 3 Linear regression models incorporating clinical, metabolic and treatment-related factors as predictors of MCCB composite score and the
working memory domain at end-point
MCCB composite end-point score
Predictors
R-squared Model df F-statistic P value Beta-coefficient T-value P value
0.58 8,41 9.53 <0.01
BMI change score 1.17 2.38 0.02**
Age 0.25 1.06 0.30
Sex −3.00 −1.04 0.31
Modal antipsychotic dose −0.04 −0.10 0.92
Treatment weeks −0.03 −0.19 0.85
Substance use 1.27 0.41 0.69
Baseline MCCB composite score 0.70 6.75 <0.01**
Baseline BMI −0.58 −1.67 0.10
MCCB working memory end-point score
Predictors
R-squared Model df F-statistic P value Beta-coefficient T-value P value
0.49 7,47 8,37 <0.01
BMI change score 0.89 2.40 0.02**
Age −0.03 −0.15 0.88
Sex 0.04 0.02 0.99
Modal antipsychotic dose 0.45 1.31 0.20
Treatment weeks 0.05 0.32 0.75
Baseline MMCCB working memory 0.57 6.46 <0.01**
Baseline BMI −0.43 −1.49 0.14
BMI Body mass index, MCCB MATRICS Consensus Cognitive Battery, ** statistically significant
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working memory performance in non-users, adjusting for age,
sex, modal antipsychotic dose, treatment duration and base-
line cognitive score (R2 = .55, F(6,25) = 7.35 p < 0.01). In
contrast, low baseline BMI predicted poorer working memory
at end-point in substance users (β = 1.22, p = 0.04) adjusting
for the same covariates (R2 = .55, F(6,17) = 4.66, p < 0.01).
Discussion
The main finding from this study was that increased BMI over
12 months of treatment predicted better overall cognition and
working memory performance in antipsychotic-naïve or min-
imally treated first episode schizophrenia spectrum disorder
patients, independent of the degree of antipsychotic exposure.
In contrast, substance use and weight loss were both associat-
ed with lower end-point working memory scores. Our find-
ings are in agreement with those from previous studies dem-
onstrating an association between weight gain and symptom-
atic improvement in schizophrenia (Raben et al. 2018). In
addition, they expand on previous research by suggesting that
an increase in BMI over the course of antipsychotic treatment
is associated with favorable overall cognitive outcome and
better working memory performance.
There are several possible explanations for the associ-
ation between weight gain and better cognitive perfor-
mance at end-point evident from our study. Firstly, chang-
es in serotonin signaling may be involved, with 5HT re-
ceptor blockade being implicated in antipsychotic-induced
weight gain (Panariello et al. 2011) and improvement in
cognitive performance (Schmitt et al. 2006). In contrast,
aberrant 5HT transmission has been implicated in poor
cognitive functioning in animal and human studies
(Strac et al. 2016) with 5HT receptor agonists known to
not only impair working memory performance (Luciana
et al. 1998), but also decrease appetite and promote
weight loss (Halford et al. 2011). In this context,
flupenthixol is known to exhibit 5HT receptor blockade
(Wiesbeck et al. 2003) which may underscore its effects
on both weight gain (Chiliza et al. 2015) and cognitive
improvement (Olivier et al. 2015) previously demonstrat-
ed in our larger study cohort. Secondly, glucose metabo-
lism and altered insulin signaling have been proposed as
common mechanisms underscoring the effects of weight
gain on symptomatic improvement in schizophrenia
(Girgis et al. 2008). Weight gain is known to increase
levels of insulin, the acute administration of which has
been shown to improve cognitive performance (Shemesh
et al. 2012). Similarly, acute administration of glucose
improves memory in schizophrenia patients (Newcomer
et al. 1999). Indeed, insulin plays a key role in modulat-
ing the level and activity of neurotransmitters including
serotonin in brain regions such as the hippocampus and
hypothalamus (Umbriaco et al. 1995; Orosco et al. 2000;
Dickinson and Harvey 2009). Important metabolic chang-
es considered deleterious in chronic schizophrenia may
therefore be considered favorable in antipsychotic-naïve
patients in the acute stage of treatment.
In the present study, weight loss and substance use were
both associated with poorer working memory at end-point,
with the majority of patients who lost weight testing positive
for substance over the course of treatment. It remains unclear
whether weight loss is associated with worsening of psycho-
pathology symptoms in schizophrenia (Chukhin et al. 2016),
and most studies have shown that weight loss has a beneficial
effect on cognition in obese individuals (Smith et al. 2010).
Therefore, the influence of weight loss evident in our study
may rather reflect the effects of substance use on working
memory performance. Interestingly, multiple studies have
shown that cannabis use in particular is associated with better
working memory performance in first-episode psychosis pa-
tients, as demonstrated in a meta-analysis by Yücel et al.
(2012). However, a meta-analysis by Sanchez-Gutierrez and
colleagues (Sanchez-Gutierrez et al. 2018) concluded that on-
going cannabis use in first-episode psychosis may exert dele-
terious effects on cognition. In accordance with our study,
findings from a recent meta-analysis of 14 studies by Bogaty
et al. (2018) further suggest that comorbid cannabis use is
indeed associated with poorer working memory performance
in early-onset psychosis.
We further demonstrated the favorable effects of low base-
line BMI as a predictor of better working memory in sub-
stance non-users, who showed a significant increase in BMI
o v e r t h e c o u r s e o f o u r s t u d y, a s w e l l a s a
significant improvement in working memory from baseline
to end-point. Low baseline BMI may represent a favorable
prognostic indicator in antipsychotic-naïve, substance non-
using patients, who are also at greater risk for weight gain
(Basson et al. 2001; Kinon et al. 2005; Raben et al. 2018).
The favorable effects of a low baseline BMI in the context of
weight gain is further evidenced by its association with symp-
tomatic remission and recovery in schizophrenia (Novick
et al. 2007, 2009; Stauffer et al. 2011). In contrast, baseline
BMI showed the opposite effect in substance users, consistent
with the observation that cannabis users did not gain signifi-
cant weight over the course of treatment in our larger sample
(Scheffler et al. 2018). Weight loss or failure to gain weight
may therefore represent a poor prognostic marker in substance
users with schizophrenia.
The present study had several important limitations, includ-
ing a short study duration and relatively small sample size,
which limited our ability to explore the putative moderating
effect of substance use on the relationship between BMI and
working memory performance. Moreover, our sample gener-
ally had a low baseline BMI, which may conceivably have
influenced our results. Furthermore, our study did not include
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the assessment of waist circumference as an indicator of cen-
tral obesity, and dietary habits and physical activity as deter-
minants of cardio-metabolic risk in schizophrenia spectrum
disorder patients treated with antipsychotics were not exam-
ined. Also, our findings are not necessarily generalizable to
other patient populations which may differ in terms of clinical
profile, treatment approach and metabolic risk profile.
However, the strength of the present study lies in the evalua-
tion of a well-characterized sample of first-episode patients,
with regular laboratory assessments, a mode of antipsychotic
delivery that was standardized, and assured adherence.
Conclusions
In conclusion, our study demonstrated that weight gain over
12 months of treatment is associated with better overall cog-
nition as well as working memory in first-episode schizophre-
nia spectrum disorder patients, independent of age, sex, and
the degree of antipsychotic exposure. In addition, our findings
suggest that substance use disrupts the relationship between
baseline BMI, weight gain and working memory in first-
episode schizophrenia spectrum disorders. Our study supports
the role of weight gain as a predictor of better cognitive per-
formance in schizophrenia. In contrast, failure to gain weight
may represent an unfavorable marker for poor working mem-
ory performance in substance users.
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A B S T R A C T
In this diffusion tensor imaging study, we explored the associations of body mass index (BMI) with white matter
microstructure in first-episode schizophrenia spectrum disorder patients (n = 69) versus healthy controls
(n = 93). We focused on fractional anisotropy (FA) measures for fronto-limbic white matter tracts known to
connect brain regions which form part of a “core eating network”. Secondary objectives included the associa-
tions of body mass with global illness severity, psychopathology and depressive symptoms. In a multivariate
analysis of covariance (MANCOVA) model, there was a significant interaction between BMI and group (patient
versus control) across the fronto-limbic white matter tracts of interest (F(1,155)= 4.91, p = 0.03). In a sub-
analysis, BMI was significantly inversely correlated with FA measures for the genu and body of the corpus
callosum, left and right tapetum, and left superior fronto-occipital fasciculus in controls. In patients, BMI was
significantly positively correlated with white matter FA for the genu of the corpus callosum and left tapetum.
Lower BMI was significantly correlated with more severe negative symptoms, as was earlier age of illness onset.
Body mass may be differentially associated with fronto-limbic white matter microstructure in first-episode
schizophrenia spectrum disorder compared to controls.
1. Introduction
Excessive body mass and schizophrenia are both associated with
white matter changes, often affecting the same tracts, including the
corpus callosum, fornix, cingulum bundle, and uncinate fasciculus
(Kubicki et al., 2005; Shimoji et al., 2013). Studying white matter
changes provides a useful neuro-anatomical basis for exploring shared
loco-regional changes in brain connectivity reported for both obesity
and schizophrenia (Cheung et al., 2008; Lee et al., 2013).
In recent years, diffusion tensor imaging (DTI) in particular has
emerged as a useful method for assessing white matter connectivity in
vivo (Kanaan et al., 2005) based on measures of water diffusion in the
brain, including fractional anisotropy (FA). Increased body mass index
as a hallmark of the metabolic syndrome is most often associated with
decreased FA in general population studies (Shimoji et al., 2013;
Xu et al., 2013). In addition, several studies have shown an association
between increased body mass index and decreased white matter FA in
bipolar disorder (Kuswanto et al., 2014; Mazza et al., 2017;
Reckziegel et al., 2018), as well as in schizophrenia patients
(Spangaro et al., 2018) and their at-risk family members
(Koivukangas et al., 2016). However, findings to date are inconsistent.
Other studies have reported an association between metabolic syn-
drome risk factors (Tang et al., 2011; Verstynen et al., 2013) including
obesity (Ou et al., 2015) and increased FA, while others still have re-
ported increased versus decreased FA across different white matter
tracts in both overweight (Carbine et al., 2020) and underweight
(Travis et al., 2015) individuals.
Taken together, the weight of the literature suggests a bi-directional
relationship between white matter connectivity and metabolic syn-
drome. Importantly, the direction of causality is often not clear. On the
one hand, obesity may lead to changes in brain structure, integrity and
connectivity; on the other, altered brain structural and functional
connectivity may predispose towards weight gain, not only in the
general population (Smucny et al., 2012; Metzler-Baddeley et al., 2013;
https://doi.org/10.1016/j.pscychresns.2020.111173
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Park et al., 2016), but also schizophrenia patients (Savransky et al.,
2017; Homan et al., 2019). In response to these knowledge gaps, the
aim of the present study was to investigate the associations of body
mass index with white matter FA in minimally treated first-episode
schizophrenia spectrum disorder patients compared to healthy controls.
We were interested in the fronto-limbic tracts known to connect dif-
ferent brain regions involved in the physiological, cognitive, emotional
and reward-based control of eating patterns and behaviours as part of a
“core eating network” (Chen et al., 2016) in humans.
Firstly, we hypothesized that body mass index would be differen-
tially associated with fronto-limbic white matter FA in patients versus
controls. We anticipated an inverse correlation between body mass
index and FA in controls, consistent with that most often reported in
general population studies (Stanek et al., 2010; Xu et al., 2013). In
addition, we hypothesised that our patients would have a lower body
mass index than controls, as previously reported for first-episode schi-
zophrenia spectrum disorders (Sugawara et al., 2018; Shah et al., 2019)
and that this would be associated with lower fronto-limbic white matter
FA, given the previously reported widespread reductions in fronto-
corticoid-limbic white matter FA in schizophrenia versus healthy con-
trols (Price et al., 2008; Schmidt et al., 2015; Asmal et al., 2017, 2019).
Lastly, we hypothesized that lower body mass index would be asso-
ciated with more pronounced psychopathology (Subramanian et al.,
2014; An et al., 2018), and that this would be most apparent for ne-
gative symptoms (Li et al., 2017; An et al., 2018; Mezquida et al., 2018;
Wei et al., 2020).
2. Materials and methods
2.1. Ethics approval
Ethics approval for the present study was obtained from the Health
and Research Ethics Committee (HREC) at Stellenbosch University (SU)
(N06/08/148). Our study was conducted in accordance with the
International Conference on Harmonization Good Clinical Practice
guidelines (International Conference on Harmonization, 1996). We
obtained written, informed consent from participants and where ap-
propriate, from a legal guardian.
2.2. Selection of study participants
The present study included minimally treated first-episode schizo-
phrenia spectrum disorder patients (n =69 ) and healthy controls
(n=93 ). The patients were recruited from first admissions to hospitals
and community clinics in the metro and rural areas of North Eastern
Cape Town, the Winelands and the West Coast over a four-year period
(2007–2011). Inclusion criteria were men and women, in- or out- pa-
tients, aged 18 to 45 years, with a first psychotic episode meeting
Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition,
Text Revisions (DSM-IV TR) (American Psychiatric Association, 1994)
criteria for schizophrenia, schizophreniform or schizoaffective disorder.
Exclusion criteria included 1) lifetime exposure to four or more weeks
of antipsychotic medication, 2) serious or unstable medical condition,
3) substance-induced psychosis, and 4) intellectual disability. Healthy
controls were recruited through word of mouth, community newspaper
advertisements, and fliers. Patients and controls were matched for age,
sex and ethnicity.
2.3. Clinical assessments
All study participants completed a general medical questionnaire
and received a thorough physical examination performed by a study
clinician, during which body weight was measured. Participants re-
moved all surplus clothing including their socks and shoes and were
weighed on an electronic scale that was regularly calibrated throughout
the study. Height was measured with a pre-fixed wall-mounted
measuring tape. Body mass index was calculated as the patient's body
weight in kilograms (kg) divided by their height in meters squared
(m2). Patients and controls were assessed using the Structured Clinical
Interview for DSM-IV (SCID) (First et al., 1994). Psychopathology was
assessed using the Positive and Negative Syndrome Scale (PANSS)
(Kay et al., 1987). In addition to PANSS total scores, we considered the
positive, negative and disorganized factor-analysis derived symptom
domains (Emsley et al., 2003). Depressive symptoms were assessed
using the Calgary Depression Scale for Schizophrenia (CDSS)
(Addington et al., 1993). Illness severity was estimated with the Clinical
Global Impression (CGI) scale (Guy, 1976). Age of onset of psychosis
was estimated based on clinical history provided by the family, relatives
or caregiver(s) of continuous onset of positive symptoms including
delusions, hallucinations, disorganized thinking or bizarre behaviour in
patients. In addition, we assessed prior and current substance use based
on self-report history. Urine toxicology for cannabis, methamphetamine
and methaqualone as the most commonly used substances in our study
cohort was also performed. Study participants were classified as “can-
nabis use positive” or “cannabis use negative”.
2.4. Neuroimaging assessment
High-resolution diffusion-weighted images (DWI) were acquired at
on an Allegra MRI scanner (Erlangen, Germany) with the following
parameters: field of view= 220 mm, spatial resolution= 1.8 mm X
1.8 mm X 1.8 mm3, repetition time= 8800 ms, echo time= 88 ms, 65
slices, no distance factor with two-fold GRAPPA acceleration. The
gradients were applied in 30 directions with b = 1000s/ms2 and a
single unweighted volume (b = 0/mm2) were also acquired. This se-
quence was repeated three times. The DWI were pre-processed using
the Functional MRI of the Brain (FMRIB) Software Library (FSL) version
4.1.8. Raw DTI data were corrected for eddy current distortions and
head motion, and the images were imported into MatLAB. The three
acquisitions were co-registered by using the first b = 0 mm/s2 as the
reference image. Outliers were determined based on the Z-value of the
tensor images estimated at the 25th and 75th percentiles. Data points
falling outside of more than three standard deviations were discarded.
The acquisitions were averaged and exported to FSL for further pro-
cessing.
In an overlapping cohort, we have previously investigated the as-
sociations of white matter FA with illness insight (Asmal et al., 2017)
and childhood trauma (Asmal et al., 2019) in first-episode schizo-
phrenia. In accordance with other DTI studies (Price et al., 2008;
Lee et al., 2013), we found widespread white matter FA reductions. In
the present study, we selected a-priori fronto-limbic white matter tracts
known to connect different areas of the brain involved in the physio-
logical (e.g. hypothalamus), cognitive-emotional (e.g. orbito-frontal
and dorso-lateral prefrontal cortex, hippocampus, amygdala) and he-
donic (e.g. ventral tegmental area, nucleus accumbens) control of me-
tabolism, appetite, satiety and reward (Chen et al., 2016). These tracts
were: the corpus callosum (body, genu and splenium), fornix, tapetum,
superior fronto-occipital fasciculus, fornix crus/stria terminalis, cin-
gulum bundle, cingulum of the hippocampus, and the uncinate fasci-
culus. Importantly, these tracts are known to be affected in schizo-
phrenia (Price et al., 2008; Kuswanto et al., 2012; Lee et al., 2013).
2.5. Statistical analysis
Statistical analyses were performed using the R software package
(3.2.4) and IBM SPSS software program (version 25). Categorical
variables were described using cross-tabulation and frequency tables,
and compared between patients and controls using a Chi-squared test.
Normally distributed numerical data were described as the means along
with standard deviation, and compared between study groups (e.g.
patient versus control, male versus female) using a student's t-test. If the
best-fitting log-transformation of non-normal continuous data remained
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so, they were described as the median along with inter-quartile range,
and compared between groups using the Wilcoxon rank sum test. For
our main analysis, fronto-limbic white matter FA measures across the
abovementioned tracts of interest were entered as dependant variables
into a multivariate analysis of covariance (MANCOVA) modelling for
the interaction between study group (patient versus control) and body
mass index, adjusting for age, sex and cannabis use as covariates.
Pearson correlation coefficients were then used to investigate the spe-
cificity and directionality of findings evident from our main analyses
(i.e. the associations of body mass index with fronto-limbic white
matter in patients versus controls), as well as to explore the associations
of body mass index with age of psychosis onset, global illness severity
(CGI), psychopathology (PANSS total scores, positive, negative, dis-
organized domains) and depressive symptoms (CDSS) in patients. A p-
value of <0.05 was used to indicate statistical significance.
3. Results
3.1. Characteristics of study group
The present study included 69 patients and 93 controls, matched for
age, sex and ethnicity (Table 1). Body mass index was significantly
lower in patients (21.37 kg/m2) versus controls (23.76 kg/m2)
(t= 2.99, p<0.01). The distribution of body mass index categories also
differed significantly between these two groups (X2= 10.70,
p= 0.013), with a preponderance of overweight and particularly obese
participants in controls compared to the patient group (Table 1). In
controls, body mass index was significantly lower in males compared to
females (t= −4.19, p<0.01), as well as cannabis users compared to
non-users (t= −3.75, p<0.01). These differences were however not
significant in the patient group (p<0.05).
3.2. Associations of body mass index with fronto-limbic white matter fa in
patients versus controls
MANCOVA identified a significant interaction between body mass
index and group (patient versus control) across the fronto-limbic white
matter tracts of interest, independent of age, sex and cannabis use (F
(1155)= 4.91, p = 0.03). In a sub-analysis, we found significant in-
verse correlations between body mass index and FA measures for the
genu (r= −0.21, p = 0.04) and body (r = −0.27, p<0.01) of the
corpus callosum, the left tapetum (r = −0.25, p = 0.01) and right
tapetum (r = −0.27, p<0.01), as well as the left superior fronto-
occipital fasciculus (r=−0.21, p= 0.04) in controls. In contrast, body
mass index was significantly positively correlated with FA measures for
the genu of the corpus callosum (r = 0.27, p = 0.03) and left tapetum
(r = 0.26, p = 0.03) in patients. In summary, there was a differential
association of body mass index with FA for the genu of the corpus
callosum and left tapetum in the patient group (decreased body mass
index, decreased FA) versus controls (increased body mass index, de-
creased FA) (Fig. 1).
3.3. Associations of body mass index with illness severity and symptom
profile in patients
Lower body mass index was significantly associated with an earlier
age of psychosis onset (r = 0.26, p = 0.03) and more pronounced
negative symptoms (r= −0.28, p = 0.02). However, there were no
significant associations between body mass index and overall illness
severity (CGI), global psychopathology (PANSS total scores), the posi-
tive and disorganized factor-derived domains, or depressive symptoms
(CDSS scores) (p>0.05).
4. Discussion
In this study, we report differential associations of body mass index
with fronto-limbic white matter microstructure in minimally treated,
first-episode schizophrenia spectrum disorder patients (decreased body
mass index associated with decreased FA) compared to healthy, mat-
ched controls (increased body mass index associated with decreased
FA). Importantly, we found widespread involvement of white matter
tracts which form part of the cortico-limbic circuitry connecting key
brain regions involved in the physiological (e.g. hypothalamus, certain
brainstem nuclei), cognitive-emotional (e.g. dorso-lateral prefrontal
cortex, orbito-frontal cortex, amygdala, hippocampus) and reward-
based (e.g. ventral striatum, nucleus accumbens) regulation of appetite,
satiety and diet as part of a “core eating network” (Chen et al., 2016).
This study is to the best of our knowledge the first to report relation-
ships between body mass index, white matter FA and symptom profiles
in first-episode schizophrenia spectrum disorders.
Our finding that higher body mass index was significantly corre-
lated with lower FA measures across multiple fronto-limbic tracts in our
control group, more than a fifth (22%) of whom were obese, is in
keeping with most general population studies (Stanek et al., 2010;
Xu et al., 2013). Evidence suggests that obesity-driven mechanisms,
including oxidative stress, inflammation, immune dysregulation, and
Table 1
Socio-demographic and clinical characteristics of study group compared between patients and controls.
Patients (n = 69) Controls (n = 93) Patient versus control (unadjusted p-value)
Age (years) (mean/SD) 24.43 (6.56) 25.80 (7.48) 0.22
Sex (male,%) 49 (71%) 59 (63%) 0.40
Highest level of education (years of schooling completed) (mean/SD) 9.93 (1.99) 10.44 (1.51) 0.10
BMI (kg/m2) 21.37 (3.88) 23.76 (6.29) <0.01
BMI classification
Underweight (<18.5 kg/m2) 12 (17%) 16 (17%) 0.01
Normal weight (18.5–25.0 kg/m2) 47 (68%) 42 (45%)
Overweight (25–30.0 kg/m2) 8 (12%) 15 (16%)
Obese (>30 kg/m2) 2 (3%) 20 (22%)
Cannabis use (yes,%) 20 (29%) 28 (30%) 1.00
Treatment-naive (yes,%) 44 (64%) –
Duration of treatment in non-naive patients, days (mean/SD) 11.60 (7.11) –
Age of psychosis onset (mean/SD) 23.90 (7.17)
PANSS Total score (mean/SD) 92.57 (15.64) –
PANSS Positive symptom factor-analysis derived domain (mean/SD) 17.23 (3.44) –
PANSS Negative symptom factor-analysis derived domain (mean/SD) 19.09 (5.12) –
PANSS Disorganized symptom factor-analysis derived domain (mean/SD) 11.51 (3.12) –
Clinical Global Impression scale (mean/SD) 3.72 (0.62) –
Calgary Depression Scale for Schizophrenia (mean/SD) 3.57 (4.28) –
BMI= body mass index; PANSS= Positive and Negative Syndrome Scale; SD= standard deviation.
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hypothalamic-pituitary-adrenal (HPA) axis dysfunction, may contribute
to changes in white matter microstructure, integrity and connectivity
(Kullman et al., 2016; Samara et al., 2019). On the other hand, an ex-
planation for the association of low body mass index with low fronto-
limbic white matter FA in our patient sample is less clear, although
general population studies have reported decreased white matter in-
tegrity across several central tracts (including the anterior, frontal and
orbital regions of the corpus callosum) in normal and under-weight
compared to overweight individuals (Carbine et al., 2020). In addition,
similar findings to ours have been reported in patients with restrictive
eating disorders, in whom widespread reductions in fronto-limbic white
matter FA associated with lower body mass index have been reported
when compared to healthy controls (Hu et al., 2017; Nickel et al.,
2019). In particular, involvement of inter-hemispheric (e.g. corpus
callosum) white matter tracts is consistent with the fronto-cortico-
limbic circuitry described here under the “core eating network”. Our
finding for the left tapetum, which is mainly comprised of decussating
fibers in the splenium (Sarikcioglu et al., 2007) of the corpus callosum,
Fig. 1. Scatterplot diagrams showing the differential associations of body mass index (BMI) with fractional anisotropy (FA) measures for the genu of the corpus
callosum (above) and left tapetum (below) in patients versus healthy controls. In patients, BMI was positively correlated with white matter FA for these tracts; in
contrast, an inverse correlation between BMI and white matter FA was evident for healthy controls.
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is of interest, since structural abnormalities of the tapetum have also
been linked to more severe positive symptoms and a longer duration of
untreated psychosis (Lee et al., 2018).
A possible neurobiological explanation for our findings in patients
could lie in the fact that oligodendrocytes are highly energy-dependant,
with effective myelination being dependant on a favourable metabolic
milieu (Bartzokis et al., 2007). Important micro-nutrient deficiencies
associated with impaired myelination capacity (Bartzokis, 2011), in-
cluding decreased iron, folate and vitamin B12 levels, have been re-
ported in schizophrenia (Williamson et al., 2015; Firth et al., 2018). In
addition to overeating, restrictive eating patterns and underweight
have been described in schizophrenia patients (Kouidrat et al., 2014).
Emerging literature further suggests that treatment-naïve patients with
first-episode schizophrenia respond differently to food cues, and this in
turn may affect changes in appetite and metabolic status over the
course of antipsychotic treatment (Stip et al., 2012; Borgan et al.,
2019). Low body mass index may therefore be a proxy measure for
micro-nutrient deficiencies and secondary metabolic abnormalities as-
sociated with poorer myelination capacity (Takahashi et al., 2011;
Maas et al., 2017).
In keeping with the effects of weight gain as a predictor of psy-
chopathology improvement in first-episode psychosis (Luckhoff et al.,
2019a), multiple studies have shown that lower body mass index is
associated with more severe psychopathology in schizophrenia
(Subramanian et al., 2014; An et al., 2018). In particular, negative
symptoms have been associated with lower body mass index in chronic
patients (Li et al., 2017; Mezquida et al., 2018; Wei et al., 2020) and
those at clinical high-risk for psychosis (Caravaggio et al., 2017), which
is similar to our finding in this first-episode sample. This is also con-
sistent with our previous findings of an unfavourable association be-
tween low baseline body mass index and poorer end-point working
memory performance after 12 months of treatment first-episode psy-
chosis, at least for cannabis users (Luckhoff et al., 2019b). Furthermore,
low body mass index has been linked with poorer treatment outcomes
in schizophrenia across multiple domains, including treatment failure
(Chiliza et al., 2015), a longer time to respond to treatment
(Schwarz et al., 2012) and shorter time to relapse (Stauffer et al., 2011).
There are several possible explanations for the correlation between
lower body mass index and more pronounced negative symptoms evi-
dent from our study, which remained significant when adjusting for sex
and cannabis use. Firstly, certain negative symptoms, particularly an-
hedonia, may contribute to poor self-care and diet, reflected by a lower
body mass index in patients (Mezquida et al., 2018). Also, other ne-
gative symptoms, including social withdrawal and a sedentary lifestyle,
may affect diet, exercise and eating patterns, thereby contributing to
weight gain (Dipasquale et al., 2013; Sicras-Mainar et al., 2014; Storch-
Jakobsen et al., 2018; Ulloa et al., 2018). However, dietary and lifestyle
factors are unlikely to fully explain the consistently reported link be-
tween low body mass index and negative symptoms. Finally, body mass
index may serve as a proxy marker for other determinants of illness
severity (Chiliza et al., 2015). For example, an earlier age of onset has
emerged as an important predictor of greater illness severity, more
pronounced negative symptoms, psycho-social impairment, and poorer
treatment outcomes in schizophrenia (Kao and Liu, 2010;
Immonen et al., 2017). Indeed, we found that age of onset was sig-
nificantly correlated with negative symptoms (r= −0.37, p = 0.001).
Furthermore, an association between lower body mass index and an
earlier age of onset has been reported (Wei et al., 2020), although an-
other study did not find this (Nadalin et al., 2018).
The identification of body mass index as a metabolic correlate of
negative symptom severity in our study could have implications for
patient care. Our findings for body mass index, age of onset and ne-
gative symptoms as inter-related determinants of illness severity and
treatment outcome hint at an extended role for metabolic assessment
beyond cardiovascular risk screening to include clinical prognostication
in first-episode psychosis. The definition and conceptualization of
negative symptoms, as well as our understanding of their temporal
course, clinical burden, and effects on treatment outcome, have un-
dergone considerable developments in recent years (Correll and
Schooler, 2020). Since the accurate assessment of negative symptoms is
critical to their appropriate management, new instruments have been
developed to assess them, such as the Brief Negative Symptom Scale
(Kirkpatrick et al., 2011) and Clinical Assessment Interview for Nega-
tive Symptoms (Kring et al., 2013). The use of the PANSS to assess
negative symptoms has been subject to criticism (Lindenmayer, 2017;
Correll and Schooler, 2020). Numerous factor analytical studies have
identified a negative symptom domain that differs on several items
from the original negative subscale (Emsley et al., 2003). For that
reason, we opted to calculate a factor analysis-derived negative
symptom domain. This echoes the approach used in our prior research
examining the associations of metabolic syndrome risk factors for
psychopathology improvement in first-episode schizophrenia spectrum
disorders (Luckhoff et al., 2019a). The value of factor-analysis in ex-
ploring the relationship between body mass index and negative symp-
toms was further described in a study of chronic schizophrenia patients
conducted by Mezquida et al. (2018).
Our study had several important strengths. Firstly, we included a
well-characterized patient sample, and could minimise the confounding
effects of prior treatment exposure, since cases were largely anti-
psychotic-naive. Secondly, our study had a relatively large sample size,
and included a matched, healthy control group. Thirdly, we used a
validated methodological approach for tract-based comparison of white
matter FA using a previously described neuroimaging protocol
(Asmal et al., 2017, 2019). However, several limitations are also ac-
knowledged. Firstly, we focused on body mass index rather than other
anthropometric measures, and did not include other metabolic syn-
drome features in this analysis. In addition, this was a cross-sectional
study, unable to assess longitudinal changes in our sample. Secondly,
our sample was collected from a largely socio-economically dis-
advantaged population, and as such, it may not always be possible to
generalize our results to other patient populations. Thirdly, although
our sample is relatively large for a single-site DTI study, we lacked
statistical power to detect more subtle associations. Fourthly, as de-
scribed above, use of a specific scale for negative symptoms may have
better assessed this symptom domain. Finally, as we did not correct for
multiple comparisons, our findings should be considered to be hy-
pothesis-generating only.
5. Conclusions
We found that body mass index was differentially associated with
fronto-limbic white matter FA in first-episode schizophrenia spectrum
disorder patients compared to healthy controls. While we replicated an
association between overweight and reduced FA in healthy controls, a
reverse association was found in patients, that may be linked to age of
onset of illness and severity of negative symptoms. Future studies
should examine the temporal effects of antipsychotic exposure on white
matter microstructure, changes in body mass, and treatment outcome in
first-episode schizophrenia spectrum disorders. More research is needed
on how different weight gain trajectories over the course of treatment
are related to sub-cortical brain regions involved in the regulation of
appetite and satiety in humans.
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A B S T R A C T
In this study, we explored the relationship between baseline hippocampal subfield volumes and change in body
mass over 12 months of treatment in 90 first-episode schizophrenia spectrum disorder patients (66 males, 24
females; mean age= 24.7 ± 6.8 years). Body mass index was assessed in patients at baseline, and at months 3,
6, 9 and 12. Hippocampal subfields of interest were assessed at baseline using a segmentation algorithm included
in the FreeSurfer 6.0 software program. Linear regression revealed a significant interactive effect between sex
and anterior hippocampus size as predictors of change in body mass over 12 months, adjusting for age, substance
use, and treatment duration. In an exploratory post-hoc sub-analysis, partial correlations showed a significant
association between weight gain and smaller CA1, CA3 and subiculum volumes in females, but not males, ad-
justing for age and substance use, with similar trends evident for the CA4 and presubiculum subfields. In con-
clusion, our findings suggest that smaller anterior hippocampal subfields at baseline are associated with the
development of weight gain over the course of treatment in first-episode schizophrenia spectrum disorders in a
sex-specific fashion. This may be related to the greater increase in body mass evident for female patients in our
study.
1. Introduction
Hippocampal structural and functional abnormalities are implicated
in the pathophysiology of schizophrenia (Heckers and Konradi, 2002;
Lieberman et al., 2018). In addition to widespread bilateral volume
reductions as a consistent finding in both first-episode and chronic
schizophrenia (Velakoulis et al., 2006; Adriano et al., 2012) localized
changes across different hippocampal regions have also been reported
early in the disease state (Li et al., 2018). In particular, more anterior
subfields including the cornus ammonis (CA) and subiculum regions are
preferentially affected in first-episode schizophrenia, with extension to
include more posterior regions as the illness progresses (Narr et al.,
2004; Kawano et al., 2015; Ho et al., 2017; Ota et al., 2017;
Baglivo et al., 2018; Haukvik et al., 2018; McHugo et al., 2018;
Nakahara et al., 2018). Moreover, smaller hippocampal subfield vo-
lumes may predict illness onset in those at high-risk for psychosis, and
have been associated with more severe psychopathology and poorer
cognitive performance in some (Kuhn et al., 2012; Zierhut et al., 2013;
Makowski et al., 2017; Ota et al., 2017) but not all (Kawano et al.,
2015; Baglivo et al., 2018) studies. Hippocampal subfield volume
alterations could therefore represent an important biological marker in
first-episode schizophrenia (Nakahara et al., 2018).
The hippocampus is functionally related to other brain regions
which form part of a “core eating network” in humans (Chen et al.,
2018). In this context, the hippocampus plays an important part in the
cognitive control of eating, in keeping with its role in memory con-
solidation and reward-based decision-making (Davidson et al., 2007;
Berthoud et al., 2017; Kanoski and Grill, 2017; Higgs and
Spetter, 2018). Hippocampal dysfunction is therefore associated with
greater responsiveness to food intake and satiety cues, leading to in-
creased appetite and resultant weight gain (Hargrave et al., 2016;
Mestre et al., 2017). Importantly, since hippocampal neurons are highly
susceptible to vascular injury, increase in body mass in turn may con-
tribute to structural damage to the hippocampus, as evident in the
general population (Taki et al., 2008; Cherbuin et al., 2015). Increased
body mass has also been correlated with smaller brain volumes in both
schizophrenia (Emsley et al., 2015) and bipolar disorder (Bond et al.,
2011, 2014). However, findings for the hippocampus remain largely
unclear (Viana-Sulzbach et al., 2016; Bond et al., 2017). In particular,
little is known about how structural and functional hippocampal
https://doi.org/10.1016/j.pscychresns.2020.111084
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abnormalities could influence change in body mass over time in first-
episode schizophrenia. This is important, since treatment-naive patients
are predisposed towards the development of weight gain and other
metabolic syndrome changes (Strassnig et al., 2007). Indeed, altered
structural and functional connectivity of brain regions implicated in
reward processing, memory consolidation, appetite regulation, arousal
and salience has been shown to differentiate between obese and
normal-weight individuals in the general population (Gupta et al.,
2015; Park et al., 2018). In this context, structural variation across
different sub-cortical areas including the striatum (Homan et al., 2019)
and hippocampus (Letourneau et al., 2011) implicated in appetite
regulation and food intake could play a role in antipsychotic-induced
weight gain in schizophrenia patients.
These observations provided the scientific rationale for the present
study, in which we sought to investigate the influence of anterior hip-
pocampal subfield volumes as predictors of change in body mass tra-
jectories of 12 months of treatment, in relation to age, sex, baseline
body mass, and substance use. We focused our analysis on the hippo-
campus as an important food intake control center (Liu and
Kanoski, 2018) involved in regulation of appetite, energy homeostasis,
and metabolism (Cenquizca and Swanson, 2006). Our focus on weight
gain was motivated by a significant increase in BMI over 12 months
evident in our larger study sample (Chiliza et al., 2015) which corre-
lated with both psychopathology improvement (Luckhoff et al., 2019a)
and better end-point cognitive performance including working memory
(Luckhoff et al., 2019b). Firstly, we hypothesized that smaller subfield
volumes, particularly for the anterior hippocampus preferentially af-
fected in early schizophrenia (Nakahara et al., 2018) and obesity
(Mole et al., 2016), would be associated with weight gain. Secondly,
given known differences in brain volume and risk for metabolic syn-
drome evident between male and female schizophrenia patients, we
hypothesized that this effect would be sex-specific (Kraal et al., 2017;
Egloff et al., 2018).
2. Methods
2.1. Ethics approval and study design
Ethics approval for the present longitudinal study was obtained
from the Health and Research Ethics Committee (HREC) at Stellenbosch
University (SU) (N06/08/148). We obtained written, informed consent
from participants and where appropriate, from a legal guardian. The
present study was conducted in accordance with the Code of Ethics of
the World Medical Association (Declaration of Helsinki).
2.2. Selection of study participants
The present study included first-episode, largely treatment-naïve
schizophrenia spectrum disorder patients recruited from first admis-
sions to hospitals and community clinics in the metro and rural areas of
North Eastern Cape Town, the Winelands and the West Coast over a
four-year period (2007–2011). Inclusion criteria were men and women,
in- or out- patients, aged 18 to 45 years, with a first psychotic episode
meeting Diagnostic and Statistical Manual of Mental Diseases, Fourth
Edition, Text Revisions (DSM-IV-TR) (American Psychiatric
Association, 1994) criteria for schizophrenia, schizophreniform or
schizoaffective disorder. Exclusion criteria included 1) lifetime ex-
posure to four or more weeks of antipsychotic medication, 2) serious or
unstable medical condition, 3) substance-induced psychosis, and 4)
intellectual disability. Healthy controls were recruited from the same
catchment areas through either personal contact or advertisements.
2.3. Antipsychotic treatment
Patients were treated with flupenthixol decanoate. Long-acting in-
jectable antipsychotics improve adherence and have demonstrated
efficacy and tolerability when used in the early phase of illness
(Emsley et al., 2013). Treatment was initiated based on a fixed protocol,
with a lead-in period of seven days, during which patients were treated
with oral flupenthixol 1–3 mg/daily followed by flexible doses of flu-
penthixol decanoate (starting dose= 10 mg intramuscular two-weekly).
The lowest possible dosage was maintained, and medication was only
increased when treatment response was insufficient. Lorazepam, bi-
periden, orphenadrine, propranolol and antidepressants were permitted
as concomitant medications. However, to minimize the potential effects
of additional treatment on metabolic status, benzodiazepines, antic-
holinergic medications and propranolol were not allowed within 12 h of
the time of assessment. Additional prohibited medications included
other antipsychotics, mood stabilizers and psychostimulants.
2.4. Patient assessments
Body weight was measured at baseline and again at months 3, 6, 9
and 12. Patients were asked to remove all surplus clothing and weighed
on an electronic scale that was calibrated regularly throughout the
study. Height was measured with a pre-fixed wall-mounted measuring
tape to the nearest centimetre (cm). Body mass index (BMI) was cal-
culated as the body weight of the patient in kilograms (kg) divided by
their height in meters squared (m2). Urine toxicology for cannabis,
methaqualone and methamphetamine (the most frequently used sub-
stances in the patient community) was performed at baseline, and again
at months 3, 6 and 12. Patients were classified as substance use positive
if they tested positive for any of these substances over the course of the
study.
2.5. Structural magnetic resonance imaging
High-resolution T1-weighted data were acquired on an3T Allegra
MRI scanner (Erlangen, Germany) at the Cape Universities Brain
Imaging Center (CUBIC), Tygerberg, Cape Town. All scans were
screened by an experienced radiologist for intracranial pathology and
inspected for motion artefacts. In total, 95 patients and 98 controls
were scanned at baseline using an MPRAGE sequence (2080 ms re-
petition time; 4.88 ms echo time, Field of view: 230 mm, 176 slices,
0.9 mm X 0.9 mm X 1 mm voxel size). Five patients and six controls
were excluded based on inferior scan quality, thus the analysis sample
comprised 90 patients and 92 controls.
2.5.1. Image pre-processing
Scans were processed and analysed using FreeSurfer stable release
version 6.0. (http://surfer.nmr.mgh.harvard.edu) (Fischl, 2012).
Briefly, slices were re-sampled to a three-dimensional image with 1 mm
isotropic voxels. Non-uniform intensity normalization was then per-
formed, after which images were registered to the Montreal Neurolo-
gical Institute (MNI) space. A second normalization step was then
performed with a different algorithm in which control points were
automatically identified and normalized to a standard intensity value,
followed by an automated skull strip procedure. Gross brain anatomy
was delineated into cortical and subcortical labels. Reconstructions
were performed with custom batching scripts on the center for High
Performance Computing (CHPC) (Rosebank, Cape Town) Sun Intel
Lengau cluster (http://www.chpc.ac.za/).
2.5.2. Hippocampal subfield segmentation
Subfields were segmented using an algorithm included in FreeSurfer
6.0 which is based on a computational atlas built from ex-vivo MRI data
of postmortem medial temporal tissue acquired on a 7 Tesla scanner as
well as an in-vivo atlas which provided information regarding adjacent
extra hippocampal structures (Iglesias et al., 2015). All subfields were
corrected for estimated total intracranial volume. In order to further
limit the number of analyses performed, left and right hippocampal
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volumes for the subfields were summed. Subfield volumes were also
log-transformed prior to analyses. We grouped the subfields into ante-
rior and posterior hippocampal subfields, as previously described
(Zeidman and Maguire, 2016; Zeidman et al., 2016). Anterior hippo-
campal subfields of interest included the CA1, CA3 and CA4 subregions,
as well as the subiculum, presubiculum, and parasubiculum. In com-
parison, posterior subfields of interest included the granule cell layer of
the dentate gyrus, (GC), molecular layer of the dentate gyrus (ML),
hippocampus–amygdala transition area (HATA), hippocampal tail, and
fimbria.
2.6. Statistical analysis
Statistical analysis was performed using R Studio software.
Categorical data (e.g. sex, substance use) were described as percentages
or frequencies, and compared between patient groups using a Chi-
squared or Fisher's exact test, as appropriate. For numerical data, nor-
mality of distribution was established using the Shapiro-Wilk test.
Normally distributed data were described as the means along with
standard deviation (SD). Non-normal data was log-transformed prior to
analysis. If the best-fitting log-transformed data was still not normally
distributed, data were described as the median along with interquartile
range. Analysis of variance was used to compare continuous numerical
data between patients and controls. End-point scores for BMI were
calculated as the last observation carried forward (LOCF). BMI change
scores were calculated as the difference between the end-point and
baseline scores. Linear mixed models for repeated measures (MMRM)
were used to assess visit-wise changes in body mass over time, in-
corporating fixed terms for age, sex, and substance use. Linear regres-
sion models and partial correlations were used to explore the influence
of hippocampal volumes on change in body mass over time in relation
to age, sex, substance use, and antipsychotic treatment duration. The
Benjamini-Hochberg method was used to correct for multiple compar-
isons in our post-hoc analyses. A p-value of 0.05 was used to indicate
statistical significance, while a p-value below 0.10 was used to indicate
trend associations.
3. Results
3.1. Baseline characteristics of study sample
The present study included 90 minimally treated or antipsychotic-
naive patients with first-episode psychosis (66 male, 24 female; mean
age= 24.7 ± 6.8 years) and 92 healthy controls (57 males, 35 fe-
males, mean age= 25.8 ± 7.5 years). There was no significant dif-
ference between patients and controls for age or sex
(Table 1).Hippocampal subfield volumes of interest (i.e. CA1, CA3,
CA4, subiculum, presubiculum, parasubiculum, granule cell layer of the
dentate gyrus, molecular layer of the dentate gyrus, hippocampal-
amygdala transition area, tail and fimbria) did not differ significantly
between patients and controls (Table 1). However, baseline body mass
was significantly lower in patients compared to controls (p = 0.011).
3.2. Characteristics of patient group
The majority of patients had a DSM-IV-TR diagnosis of schizo-
phrenia (n = 62, 69%), while 27 patients (30%) were diagnosed with
schizophreniform disorder, and one patient (1%) had a diagnosis of
schizoaffective disorder. Our sample consisted mostly (n = 72; 74%) of
patients of Mixed Ancestry, and also included 13 Black African (15%)
and five Caucasian (11%) patients. A total of 34 patients (38%) were
classified as substance use positive based on urine toxicology for can-
nabis, methamphetamine or methaqualone use. Mean treatment dura-
tion was 42 weeks. The mean modal dose of flupenthixol decanoate was
10 mg in 45 patients, 15 mg in 18 patients, 20 mg in nine patients, 5 mg
in three patients, and 25 mg in one patient. Male patients were sig-
nificantly more likely to report a history of substance use (p = 0.018),
while females tended to be older (p = 0.063).In accordance with prior
studies conducted in first-episode schizophrenia samples (Egloff et al.,
2018), we found that, while male patients had larger total intracranial
volumes, all corrected hippocampal subfield volumes except the fimbria
were significantly larger in female patients, as shown in Table 2.
3.3. Change in body mass index over 12 months of treatment in patients
MMRM analysis showed a significant sex*time interaction
(p = 0.01) (Fig. 1), whereby female patients (least significant differ-
ence= 4.89 kg/m2) gained weight to a greater extent over the course of
the study than males (least significant difference= 2.29 kg/m2), ad-
justing for age and substance use. In total, 72 patients had at least one
post-baseline body mass assessment used to determine weight gain over
time. From this subgroup, 52 patients (72%) had complete data for all
body mass index assessments, including for month 12. In comparison,
six patients (8%) had their last assessment at month 9, seven patients
(10%) had their last assessment at month 6, while another seven pa-
tients (10%) had only one follow-up body mass assessment at month 3.
3.4. Hippocampal volumes as a predictor of weight gain in patients
In the total patient sample, there were no significant correlations
between baseline body mass and hippocampal subfield volumes
(p>0.05). In addition, we failed to demonstrate a significant correla-
tion between weight gain (i.e. the BMI change score) and either anterior
(rho= −0.10, p = 0.327) or posterior (rho= −0.07, p = 0.506)
Table 1
Comparison of hippocampal subfield volumes between patients and controls.
Patient characteristic Patients (n = 90) mean (SD) Controls (n = 92) mean (SD) Unadjusted p-value (patient vs. controls)
Age (years) 24.73 (6.81) 25.80 (7.47) 0.318
Sex (male/female) 66 (73%), 24 (27%) 57 (62%), 35 (38%) 0.139
Body mass index (kg/m2) 21.76 (4.04) 23.75 (3.56) 0.011*
CA1 0.082 (0.010) 0.084 (0.011) 0.185
CA3 0.029 (0.003) 0.029 (0.004) 0.721
CA4 0.034 (0.004) 0.034 (0.004) 0.636
Subiculum 0.056 (0.007) 0.057 (0.007) 0.202
Presubiculum 0.038 (0.005) 0.039 (0.005) 0.053
Parasubiculum 0.007 (0.001) 0.008 (0.001) 0.130
Granule cell layer of the DG 0.039 (0.004) 0.040 (0.005) 0.449
Molecular layer of the DG 0.074 (0.009) 0.076 (0.009) 0.114
Hippocampus–amygdala transition area 0.012 (0.002) 0.012 (0.002) 0.140
Hippocampal tail 0.072 (0.011) 0.075 (0.012) 0.103
Fimbria 0.010 (0.002) 0.010 (0.002) 0.488
Abbreviations: CA= cornus ammonis; DG= dentate gyrus.
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hippocampal volumes in the total patient group. Linear regression
models were then used to explore the interactive effect of sex and
hippocampal volumes (sex*volume) on change in body mass over 12
months (dependent variable) in relation to age, substance use, and
treatment duration as covariates. In this analysis, we did not include
baseline body mass, since it was neither a significant predictor of
weight gain, nor significantly correlated with baseline hippocampal
subfield volumes in the total patient sample. In addition, we did not
include antipsychotic dose in our prediction models, since it was not
associated with weight gain in patients, consistent with findings evident
in our larger study cohort (Chiliza et al., 2015).
In model one (R2= 0.28, F(6,64)= 4.22, p = 0.001) there was a
significant interaction between sex and anterior hippocampal volumes
(beta= −7.78, p = 0.001) as predictors of change in body mass over
12 months, adjusting for age, substance use, and treatment duration.
Individual effects for sex, hippocampal volume and treatment duration
were also evident (Table 3). In contrast, no such interaction was evident
in model two, where posterior hippocampal volumes and sex were not
significant predictors of weight gain (Table 3).
Secondly, we used partial correlations to assess the relationships
between individual anterior subfields and change in body mass based
on these findings, with patients stratified according to sex. There were
no significant associations between change in body mass and any of the
anterior hippocampal subfields of interest in male patients. In contrast,
in female patients, smaller anterior hippocampal subfield volumes at
baseline were correlated with weight gain, adjusting for age and
Table 2
Comparison of baseline socio-demographic and clinical characteristics as well as hippocampal subfield volumes between male and female patients. .
Patient characteristics Male patients (n = 66) mean (SD) Female patients (n = 24) mean (SD) Unadjusted p-value (male vs. female)
Age (years) 23.92 (6.19) 26.96 (8.03) 0.061
History of substance use (yes/no) 31 (47%), 35 (53%) 4 (17%), 20 (83%) 0.018
Body mass index (kg/m2) 21.45 (3.36) 22.61 (5.49) 0.229
Total intracranial volume (ICV) (cm3) 1591.83 (143.17) 1341.23 (159.68) <0.001
CA1 vol (mm3) 0.080 (0.009) 0.086 (0.010) <0.001
CA3 vol (mm3) 0.028 (0.003) 0.030 (0.004) <0.001
CA4 vol (mm3) 0.033 (0.003) 0.037 (0.004) <0.001
Subiculum volume (mm3) 0.054 (0.006) 0.061 (0.009) <0.001
Presubiculum volume (mm3) 0.036 (0.004) 0.041 (0.005) <0.001
Parasubiculum (mm3) 0.007 (0.001) 0.008 (0.001) 0.002
Granule cell layer of the DG (mm3) 0.038 (0.003) 0.042 (0.005) 0.002
Molecular layer of the DG (mm3) 0.072 (0.007) 0.079 (0.011) <0.001
Hippocampus–amygdala transition area (mm3) 0.011 (0.001) 0.012 (0.002) 0.010
Hippocampal tail (mm3) 0.069 (0.009) 0.079 (0.012) <0.001
Fimbria (mm3) 0.010 (0.002) 0.010 (0.002) 0.725
Abbreviations: CA= cornusammonis; DG= dentate gyrus.
Fig. 1. Comparison of visit-wise change in mean body mass index (BMI) for visit one (baseline) to month 12 (end-point) between male and female patients. [a]: BMI
measured in kilograms (kg) per meter squared (m2) [kg/m2].
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substance use (p = 0.026) (Fig. 2). In addition, weight gain was cor-
related with smaller CA1 (p = 0.033), CA3 (p = 0.027) and subiculum
(p = 0.006) volumes in female patients, adjusting for the same con-
founders. Similar trends were evident for the CA4 (p = 0.056) and
presubiculum subfields (p = 0.056) in female patients. The association
between smaller subiculum volumes and increase in body mass re-
mained when adjusting for multiple comparisons (adjusted p-value=
0.042).
4. Discussion
In the present study, there was a significant interactive effect be-
tween sex and anterior hippocampal volumes on change in body mass
over 12 months in first-episode schizophrenia spectrum disorder pa-
tients, adjusting for age, substance use, and treatment duration. In an
exploratory post-hoc analysis, smaller hippocampal subfield volumes
were associated with weight gain in female, but not male patients, in-
dependent of age and substance use. Importantly, the association be-
tween smaller subiculum volumes and increase in body mass in female
patients remained significant following correction for multiple com-
parisons. Our findings are consistent with the known association be-
tween increased body mass and hippocampal structural abnormalities
in the general population (Taki et al., 2008; Cherbuin et al., 2015) as
well as in chronic schizophrenia patients treated with olanzapine
(Letourneau et al., 2011). However, our study extends previous re-
search, and is to the best of our knowledge the first to demonstrate an
association between anterior hippocampal size and weight gain in first-
episode schizophrenia patients.
The hippocampus is a particularly stress-sensitive brain region, and
multiple studies have shown that increased body mass contributes to
hippocampal volume loss via several mechanisms, including altered
cortisol metabolism and hypothalamic-pituitary-adrenal axis dysregu-
lation. These factors are in turn associated with excitotoxicity, dendritic
damage, and neuronal cell death, ultimately leading to impairment in
structural integrity of the hippocampus (Mondelli and Howes, 2014;
McEwen et al., 2016). However, emerging evidence also shows the
importance of the hippocampus in the regulation of food intake and
satiety (Hargrave et al., 2016) due in part to its involvement in
memory, inhibition and decision making (Davidson et al., 2019). In-
deed, the hippocampus is intimately connected to other components of
the “core eating network” in humans, and is active at the interface
between the physiological, hedonic and cognitive control of eating
Table 3
Linear regression models showing the interactive effects between sex and hip-
pocampal volume as predictors of change in body mass over 12 months in re-
lation to age, substance use and treatment duration as covariates.
MODEL 1: R2= 0.28, F(6,64)= 4.22, p = 0.001
Predictors
Beta-coefficient T-value p-value
SEX (male/female) −66.35 −3.23 0.002
AHV 3.03 2.03 0.046
AGE (years) −0.05 −1.10 0.278
TREATMENT DURATION (weeks) 0.06 2.26 0.027
SUBSTANCE USE (yes/no) −1.27 −1.98 0.052
SEX*AHV (interaction) −7.70 −3.32 0.001
MODEL 2: R2= 0.19, F(6,64)= 2.42, p = 0.036
Predictors
Beta-coefficient T-value p-value
SEX (male/female) −20.37 −1.27 0.209
PHV 2.18 1.16 0.250
AGE (years) −0.06 −1.30 0.198
TREATMENT DURATION (weeks) 0.06 1.98 0.053
SUBSTANCE USE (yes/no) −1.11 −1.58 0.119
SEX*PHV (interaction) −2.84 −1.39 0.170
Abbreviations: AHV= anterior hippocampal volume; PHV= posterior hippo-
campal volume.
Fig. 2. Scatterplot diagram showing a sig-
nificant inverse correlation between baseline
anterior hippocampal volumes and change in
body mass over 12 months of treatment in
female firs-episode schizophrenia spectrum
disorders (n = 24). BMI change score mea-
sured in kilograms (kg) per meter squared
(m2) [kg/m2] [a]; hippocampal volume
(anterior) measured in cubic millimetres
(mm3) [b].
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(Davidson et al., 2019). Our findings are therefore in keeping with the
known contribution of hippocampal dysfunction to risk for weight gain
via abnormal processing and consolidation of food-related memories
(Davidson and Jarrard, 1993), ultimately leading to greater respon-
siveness to food cues, increased appetite, and weight gain
(Hargrave et al., 2016; Mestre et al., 2017). In particular our finding of
an association between weight gain and the anterior hippocampus is
important, since it is more intimately involved in stress sensitivity,
mood and emotion via its connectivity with the insula, amygdala and
other regions compared to the posterior hippocampus, which is more
involved in spatial learning and episodic memory hippocampus
(Chase et al., 2015; Zeidman and Maguire, 2016; Dalton et al., 2019).
Higher levels of inflammation in female compared to male patients
(Lee et al., 2019) may help explain the sex-specific nature of our
findings. In schizophrenia, inflammation has been associated not only
with hippocampal dysfunction and memory impairment, but also with
risk for treatment-emergent weight gain (Kalmady et al., 2014;
Fonseka et al., 2015; Borovcanin et al., 2017). The use of antipsychotics
including flupenthixol is associated with down-regulation of in-
flammation, which could promote weight gain by counteracting anor-
exigenic signals in the brain. This could then lead to increased appetite
and a resultant increase in body weight over the course of treatment. It
thus stands to reason that, since baseline inflammation is likely higher
in females, greater down-regulation would have a more pronounced
effect on appetite and therefore on risk for weight gain.
Importantly, differences in brain-derived neurotrophic factor
(BDNF) activity between male and female patients may also be in-
volved. BDNF is known to play an important role not only in hippo-
campal neurogenesis, but also neurotransmitter metabolism, appetite
and energy homeostasis (Rothman et al., 2012). Levels of BDNF are also
known to be lower in first-episode psychosis patients compared to
controls (Green et al., 2011) a finding which has been associated with
poorer cognitive performance as well as lower hippocampus volume
(Heitz et al., 2018). Studies have further demonstrated sex influences
hippocampal BDNF expression (Yamaura et al., 2013) with lower levels
being correlated with weight gain in female, but not male schizophrenia
patients (Zhang et al., 2014; Yang et al., 2019). In addition, anti-
psychotic use in schizophrenia has been found to normalize BDNF levels
in men but not in women (Chen and Huang, 2011). Therefore, hippo-
campal dysfunction at baseline may reflect a decrease in BDNF ex-
pression, which then predisposed towards weight gain in female pa-
tients in our study. Whatever the mechanisms, our discordant findings
between males and females indicate that further research is warranted
into the role of sex in the link between hippocampal volume and body
mass in schizophrenia.
Strengths of the study include the following: first, we used a first-
episode sample, which minimized the effects of illness chronicity and
targeted patients most susceptible to antipsychotic associated weight
gain (Strassnig et al., 2007). Second, we could exclude the confounding
effects of prior treatment exposure, since this was a largely anti-
psychotic-naive sample. Third, we were able to control for the effects of
medication adherence by using a depot formulation antipsychotic.
However, we acknowledge several limitations in the current study.
Firstly, we only considered baseline hippocampal volumes in patients,
since only 38 (42%) patients successfully completed the month 12
imaging assessment. Secondly, our results may not necessarily be gen-
eralizable to other study populations with different socioeconomic and
nutritional backgrounds. Thirdly, the effect of baseline hippocampal
volume as a predictor of weight gain was limited to a relatively small
group of female patients (n = 24).Lastly, while the use of a single an-
tipsychotic in our study had the advantage of providing standardized
treatment, it also means that our results are not necessarily applicable
to individuals treated with other antipsychotics.
In conclusion, our study supports the existence of an association
between weight gain and baseline anterior hippocampal subfield vo-
lumes in first-episode schizophrenia spectrum disorder patients, and
that this association is sex-specific. We demonstrated the role of the
hippocampus as a predictor of weight gain in female patients, sug-
gesting its involvement in the development of treatment-emergent
metabolic syndrome changes. Baseline imaging could hold value in
explaining how the connectivity between key brain regions involved in
the cognitive, physiological and hedonic control of feeding influences
risk for development of antipsychotic-induced weight gain in first-epi-
sode schizophrenia. Further studies are needed in order to clarify the
sex-specific nature of our findings, as well as to what extent abnorm-
alities of brain structure affect the associations between metabolic
syndrome, symptom expression and treatment outcome.
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The present chapter provides a narrative synthesis of the main insights gathered as a result 
of the doctoral research described in this dissertation. Future research avenues are further 
discussed, and an overall conclusion provided.  
6.2. Weight Gain and Clinical Outcome in First-Episode Schizophrenia 
In accordance with our primary research objective, we found that the relationship between 
increased body mass and favourable clinical outcomes described for chronic schizophrenia 
(Sharma et al., 2014; Raben et al., 2017) also affects first-episode patients (n=106) over the 
first 12 months of treatment (Chapter II). Importantly, this effect was shown to be 
independent of the confounding effects of age, sex, substance use, and other metabolic 
syndrome changes. In addition, we demonstrated an illness-specific association between 
weight gain and improvement in the disorganized symptom domain of schizophrenia, which 
was independent not only of the degree of antipsychotic exposure, but also co-treatment 
with antidepressants and anticholinergic medications (Chapter II).  
In most prior outcome studies, chronic patients were with either clozapine or olanzapine, 
which are known for their propensity to induce weight gain (Sharma et al., 2014; Raben et 
al., 2017). In contrast, we enrolled first-episode patients treated with flupenthixol decanoate, 
which is considered relatively more weight-neutral, despite resulting in a significant increase 
in body mass over 12 months in an overlapping study cohort (Chiliza et al., 2015a). 
Furthermore, our use of a long-acting injectable antipsychotic allowed us to control for 
medication adherence (Chapter II) which represented a major strength of our research. 
Taken together, our findings argue that the association between increased body mass and 
clinical benefit described for schizophrenia is not just a reflection of higher compliance rates 





Indeed, our use of a depot formulation of treatment provided based on a standardized 
protocol ensured that we could control for patient adherence. Our research thus supports a 
fundamental and illness-specific relationship between weight gain and clinical improvement 
that is not confounded by treatment compliance. In addition to eliminating medication 
adherence as a potential confound, a similar effect for in-patient hospitalization should be 
considered. However, we note that the majority of patients (n=85; 67%) in our larger first-
episode cohort (n=126) were not hospitalized upon admission. Post-hoc testing did not 
reveal obvious differences in the socio-demographic or clinical profiles of patients stratified 
based on the need for in-patient hospitalization. The short duration of in-patient care in those 
who were hospitalized bears mention, as does the limited extent of treatment exposure prior 
to admission. This is important, since it can be argued that a longer duration of in-patient 
care would amount to higher access to psycho-social support as well as increased nutritional 
support. However, financial support in the form of social grants would be available to all 
patients following a formal diagnosis of schizophrenia being established. The anticipated 
effect of in-patient care on access to food and medical care is therefore expected to be 
limited. That being said, our research emphasizes the specific healthcare needs of 
vulnerable individuals in our own population. Future studies would do well examine the 
social determinants of barriers to healthcare access and food security in lower- to middle-
income communities. 
6.3. Body Mass Index and Clinical Outcome in First-Episode Schizophrenia 
In a follow-up study (Chapter III), we showed that the role of weight gain as a favourable 
prognostic marker is not limited to psychopathology outcomes (Chapter II), but extends to 
include better overall end-point cognition (MCCB) after 12 months of treatment in first-
episode schizophrenia spectrum disorder patients (n=72). This effect remained even when 
adjusting for relevant clinical (i.e. age, sex, substance use, baseline cognitive scores), 
metabolic (baseline body mass index) and treatment-related (mean modal antipsychotic 




(MCCB), the specific correlation between weight gain and better end-point working memory 
performance in first-episode patients (n=72) did not remain when adjusting for substance 
use and baseline body mass index in a linear regression model (Chapter III).  
Based on this finding, we performed several post-hoc tests to further explore the 
associations of body mass index with working memory performance in first-episode patients 
stratified according to substance use. First, we found that baseline body mass index was 
significantly lower in substance users compared to non-users (p=0.03). Second, substance 
use itself was associated with poorer end-point working memory performance (p=0.01), with 
a significant improvement in this cognitive domain over 12 months of treatment being limited 
to substance non-users (p=0.02). Third, low baseline body mass index was associated with 
higher end-point working memory scores in substance non-users, who gained more weight 
over 12 months of treatment compared to their non-using counterparts. In comparison, low 
body mass index was associated with poorer end-point working memory performance in 
substance users, who gained less weight, and showed prevalent weight loss over the course 
of the study, compared to non-users (Chapter III).  
The findings outlined above were deemed in accordance with those reported in an 
overlapping first-episode patient cohort (n=109), whereby cannabis users gained less weight 
over 12 months of flupenthixol decanoate treatment compared to non-users (Scheffler et al., 
2018). Similar research conducted in first-episode samples also emphasizes the lower 
propensity for cannabis-using patients to either gain weight or develop the metabolic 
syndrome as composite entity (Stiles et al., 2020). Failure to gain weight in some first-
episode patients who use cannabis could be related in part to differences in clinical outcome 
evident when compared to non-users, including a higher risk of relapse, despite similar 
overall trajectories for psychopathology and depressive symptom outcomes overall between 
the two groups (Scheffler et al., 2020). The notion that low body mass index as an intrinsic 
metabolic feature of schizophrenia (Shah et al., 2019) constitutes an unfavourable clinical 




2011), longer time to respond to treatment (Schwarz et al., 2012), and treatment failure 
(Chiliza et al., 2015b) in schizophrenia patients.  
It is further noted we found a higher prevalence of cannabis use among male compared to 
female first-episode patients across different sub-studies (Chapter II, IV). This should be 
highlighted, since male sex is a known risk factor for low body mass in schizophrenia (Wang 
et al., 2020) as well as healthy controls (Chapter IV). In addition, male patients often 
experience more pronounced negative symptoms, lower psycho-social functioning, and a 
poorer response to treatment overall compared to female patients (Ochoa et al., 2012; Li et 
al., 2016). In addition, some research (Miettunen et al., 2018; Riecher-Rossler et al., 2018) 
suggests that the age of onset is earlier in male compared to female patients, although this 
finding has not been replicated in all studies to date (Venkatesh et al., 2008; Naqvi et al., 
2010). Nevertheless, and earlier age of onset is still thought to shape the clinical expression 
and temporal course of illness in schizophrenia spectrum disorders (Kao and Liu, 2010; 
Immonen et al., 2017).  
It is thus at times difficult to disentangle the associations between cannabis use, low pre-
treatment body mass and failure to gain weight to the same degree as non-using patients 
from the potential confounding effects of biological sex and age of onset. This complexity 
was identified as an important factor to be considered in future studies exploring the effects 
of ongoing cannabis use on the temporal course of illness and clinical outcomes in first-
episode patients in relation to important socio-demographic (e.g. biological sex) and 
treatment-related (e.g. changes in body mass index) confounders.  
In particular, there is a need to examine the inverse correlation between body mass index 
and negative psychopathology evident in our patient sample (Chapter IV). This is important, 
since sex-based differences in both negative symptoms and rates of comorbid substance 
abuse have been described for schizophrenia (Abel et al., 2010; Li et al., 2016). In this 




have evolved over time (Correll and Schooler, 2020). For example, the distinction between 
its expressive and experiential aspects is now recognized. In addition, several novel 
instruments have been developed to support to examination of negative symptoms in both a 
clinical and research setting (Kirkpatrick et al., 2011; Kring et al., 2013). Future studies 
would do well to examine different aspects of clinical outcome (e.g. degree of reduction, time 
to improvement, and negative symptom persistence) in relation to its predictors and clinico-
biological correlates in first-episode schizophrenia. 
In addition, it will be important to extend our focus on the characterization of cannabis use in 
relation to metabolic status and clinical outcomes in schizophrenia. In particular, we aim to 
calculate a continuous measure of ongoing use based on the number of positive urine 
screening results over a specific time period. In addition, more examination of both cessation 
and relapse of use are envisioned. In the near future, it will also be possible to perform 
cannabinoid profiling (drug) and pharmacogenomics testing (host) in order to facilitate risk-
benefit stratification in both health and disease. This could represent an important step 
towards ethical interventional research including the use of certain cannabinoids to improve 
treatment outcomes in first-episode schizophrenia. 
6.4. Brain Structural and White Matter Connectivity Correlates of Body Mass Index in 
First-Episode Schizophrenia 
In order to better understand the role of body mass index as a predictor of illness severity 
and clinical outcome, we decided to incorporate a structural neuroimaging component as 
part of the multi-modal assessment of metabolic syndrome risk factors in our first-episode 
patient cohort. In lieu of selecting global brain structural measures (e.g. total cortical gray or 
white matter volume, subcortical gray matter), we decided to first focus our attention on 
diffusion tensor imaging (DTI) as a valuable approach used for the in vivo assessment of 




In particular, we selected fronto-limbic white matter tracts based on a priori knowledge of 
their roles in connecting diverse brain regions involved in the physiological (e.g. 
hypothalamus, brainstem), hedonic (ventral striatum, nucleus accumbens, ventral tegmental 
area) and cognitive-emotional (amygdala, hippocampus) control of feeding in humans as 
part of a “core eating network” (Chen et al., 2016). We elected to focus on fractional 
anisotropy (FA) as our main measure of interest for the following tracts: the genu, body and 
splenium of the corpus callosum, fornix, left and right tapetum, left and right superior fronto-
occipital fasciculus, left and right fornix crus/stria terminalis, left and right cingulum bundle, 
left and right cingulum of the hippocampus, as well as the left and right uncinate fasciculus 
(Chapter IV).  
In a multivariate model, we demonstrated a significant effect for body mass index across all 
fronto-limbic white matter tracts of interest in patients (low body mass index, low FA) versus 
controls (high body mass index, low FA), adjusting for age, sex, and cannabis use. In 
particular, we found that lower body mass index in first-episode schizophrenia spectrum 
disorder patients correlated with decreased FA for the genu of the corpus callosum and left 
tapetum in particular (Chapter IV). Our inclusion of a structural neuroimaging component 
alongside existing socio-demographic, clinical and metabolic data thus provided important 
evidence to suggest that the role of low baseline body mass index as a putative adverse 
prognostic marker has a neurobiological underpinning.  
Based on this foundational research, we thus extended our neuroimaging assessment to 
include structural magnetic resonance imaging (MRI) of subcortical brain regions involved in 
the regulation of appetite, satiety and reward, subsumed as part of the “core eating network” 
in humans  (Chen et al., 2016). Most of these subcortical structures are known to be 
connected via the same fronto-limbic white matter tracts we explored using DTI (Chapter IV), 
and included the amygdala, brainstem, ventral tegmental area, caudate nucleus, 
hippocampus, nucleus accumbens, pallidum, putamen, ventral diencephalon and ventral 




an area known to be active at the crucial interface between the physiological, hedonic, and 
cognitive control of appetite, satiety and reward (Chapter V).  
The decision to include the hippocampus as our main region of interest was further 
motivated by the development of novel software techniques which allow an unprecedented 
view of the individual subfields which comprise the hippocampus. We were thus interested in 
the associations of the hippocampus and its subfields with baseline body mass index and its 
temporal evolution over 12 months of treatment in our first-episode patient cohort (n=90) 
compared to healthy controls (n=92). The anterior hippocampus in particular emerged as a 
sex-specific predictor of weight gain in first-episode schizophrenia spectrum disorder 
patients, independent of age, substance use, or treatment duration. In particular, lower 
volumes for the subiculum, cornus ammonis (CA) 1 and 3 subfields were associated with a 
greater increase in body mass index over 12 months of treatment in female patients 
(Chapter V). 
In summary, the inclusion of a neuroimaging component to our research helped to reveal the 
brain structural underpinnings of body mass index and its temporal evolution over 12 months 
of treatment in first-episode schizophrenia spectrum disorders. Insight gathered as a result 
of this process prompted an initial characterization of important brain structural correlates 
which could help explain the unfavourable prognostic role of low body mass index and/or 
failure to gain weight in first-episode schizophrenia spectrum disorder patients (Chapters III, 
IV). In addition, structural neuroimaging assisted us in the identification of brain regions 
including the hippocampus which could play a role in the known differences in weight gain 







6.5. Future Research Directions  
Our research uncovered important relationships between weight gain and clinical 
improvement over the first 12 months of treatment in first-episode schizophrenia spectrum 
disorder patients treated with flupenthixol decanoate. Nevertheless, it also emphasized our 
research shortcomings, including the limited sample sizes noted for each of our individual 
studies included in this dissertation. General considerations including the need to extend our 
research scope and focus on similar patients enrolled as part of overlapping project cohorts 
should thus be considered across all specific future directions discussed below. That being 
said, we also note the sample size in terms of absolute number should be weighed against 
this being a single-site cohort study including well-characterized patients subjected to careful 
follow-up over time. In addition, our findings indeed provide the scientific rationale and 
motivation for further research into the long-term evolution of metabolic syndrome risk 
factors and their associations with treatment outcome in our first-episode patient sample. 
6.5.1. Intrinsic Weight Gain Trajectories and Long-Term Outcome in First-Episode 
Schizophrenia 
In the context of cardiovascular research, an emerging body of evidence suggests that 
obesity is associated with a favourable prognosis and decreased mortality risk in patients 
with established ischemic heart disease (Gruberg et al., 2002). In recognition of this 
apparent “obesity paradox”, researchers started to draw a theoretical distinction between 1) 
metabolically healthy obesity, characterized by its association with other metabolic syndrome 
changes, ectopic fat deposition, immune dysregulation, altered adipocytokine expression, 
low-grade inflammation and oxidative stress, and 2) metabolically unhealthy obesity, 
characterized by a dissociation from other metabolic syndrome changes, preservation of 
normal immune functioning, an intact response to insulin, as well as a favourable metabolic 




Little is however known about the long-term evolution of treatment-emergent metabolic 
syndrome risk factors in schizophrenia (Strassnig et al., 2017). It is plausible that a similar 
approach to that used in cardiovascular research (Vecchie et al., 2018) could provide novel 
insights into how different weight gain trajectories affect long-term clinical outcomes in first-
episode schizophrenia spectrum disorders. To date, we have collected comprehensive 
clinical and metabolic data on our first-episode patient cohort over the first 24 months of 
treatment. In an important first step, we aim to determine whether weight gain beyond the 
first year of treatment continues unabated, or rather tends to level off over time (Mustafa et 
al., 2019). Since serum glucose levels remained relatively stable over the first 12 months of 
treatment in our first-episode patient cohort (Chiliza et al., 2015a), an important second step 
would be to determine whether risk for Insulin Resistance (IR) and type II Diabetes Mellitus 
(DM II) increases over a more chronic period of treatment exposure (Pillinger et al., 2017; 
Jeong et al., 2018).  
Here, we anticipate that a pronounced increase in body mass index, that reaches an initial 
plateau, in addition to being dissociated from other metabolic syndrome changes, would 
represent a favourable weight gain profile associated with a good overall prognosis 
(Bhansali et al., 2017; Raben et al., 2017). In contrast, a more insidious, chronic and 
persistent elevation in body mass index beyond the first 12 months of treatment, that 
clusters with other metabolic syndrome features, could rather represent an opposing weight 
gain profile associated with an unfavourable prognosis and poorer treatment outcomes (Roth 
et al., 2016). 
In such patients, poor diet and lifestyle habits are believed to compound risk for ectopic fat 
deposition associated with altered adipocytokine expression, aberrant immune regulation, 
chronic low-grade inflammation, and oxidative stress (Roth et al., 2016). These changes can 
ultimately lead to failure of compensatory mechanisms which in turn causes acute metabolic 
changes that were once favourable to become deleterious (Vecchie et al., 2018). If such 




timeframe, increased visceral adiposity may drive metabolic abnormalities linked to an 
unfavourable clinical prognosis, poor mental health, decreased levels of functioning, and 
poor quality of life in the long-term (Agid et al., 2013; Kritharides et al., 2017).  
However, we also emphasize that a broad distinction between two weight gain trajectories 
and their association metabolic changes being consistently “favourable” versus 
“unfavourable” could belie a more complex relationship between body mass index, clinical 
improvement and treatment effects in first-episode schizophrenia spectrum disorders (Wang 
et al., 2020). 
6.5.2. Evolution of Lipid Abnormalities and Clinical Outcome in First-Episode 
Schizophrenia   
In our first-episode patient cohort (n=107), treatment with flupenthixol depot over 12 months 
resulted in a significant increase in serum triglycerides, as well as a significant decrease in 
high-density lipoprotein (HDL) cholesterol levels (Chiliza et al., 2015a). Following the 
identification of different weight gain trajectories in relation to longer-term clinical outcomes, 
an important next step would be to extend our focus to also examine the evolution of sub-
clinical lipid abnormalities using our 24-month dataset. First, we are interested in the 
proposed co-occurrence of elevated triglycerides with decreased total and low-density 
lipoprotein (LDL) cholesterol levels described for treatment-naive first-episode schizophrenia 
patients (Misiak et al., 2017; Pillinger et al., 2017) and its effects on clinical outcome over the 
first 24 months of treatment in our patient sample.  
The directional and specific natures of such lipid profile alterations are not clear-cut, and 
could be considered as being dependent on disease stage and illness chronicity, among 
other factors. For example, in a meta-analysis of 14 studies conducted by Kim and 
colleagues (2019), the authors presented the argument that an elevation in triglyceride levels 
is associated with a favourable response to treatment in schizophrenia patients, independent 




contrast, a more recent prospective evaluation of outcome data obtained from a first-episode 
psychosis patient sample (n=749) provided evidence that rather substantiates the role of 
increased triglycerides at baseline as being consistent with an unfavourable long-term 
prognosis, independent of body mass index (Osimo et al., 2020).  
In a similar fashion, several studies have also found that low cholesterol levels are 
associated with increased risk for suicide, higher levels of aggression, and impulsivity in first-
episode schizophrenia (Atmaca et al., 2003, 2007; Kavoor et al., 2017). In comparison, 
opposing studies rather suggest that high cholesterol levels are associated with more severe 
psychopathology (Devanarayanan et al., 2016), non-remission (Stratta and Rossi 2013), and 
higher depressive symptom severity (Fang et al., 2019; Gohar et al., 2019) in chronic as 
opposed to first-episode schizophrenia patients. Future research would therefore do well to 
determine whether possible increases in certain lipids including cholesterol levels following 
initial treatment exposure in first-episode patients represent a “return to baseline”, or 
aggravation of future cardio-metabolic risk, as well as how this relates to the stage of the 
disease, as well as the duration of treatment. In brief, the beneficial versus detrimental 
relationships of high versus low lipid levels is not clear-cut, and likely dependant on pre-
treatment levels, illness stage, the specific lipid fraction, and other metabolic syndrome 
features (IR, DM II) present, among other factors.  
In this context, it will soon be possible to perform more extensive lipid profiling using existing 
stored biological samples collected from our first-episode patient cohort described in this 
dissertation at an affordable price point, and use this data to predict treatment outcomes and 
tailor patient management based on individualized needs of care. For example, Tessier et 
al., (2016) used red blood cell membrane lipidomics to characterize specific phospholipid 
and fatty acid profiles in schizophrenia patients compared to healthy controls. These 
different lipid clusters showed distinct relationships with psychopathology severity and 
cognitive symptoms in the patient group. In a subsequent study, Aquino and colleagues 




patients (n=54) treated over six weeks with a second-generation antipsychotic. This 
approach allowed the researchers to differentiate responders from non-responders for 
olanzapine, risperidone and quetiapine based on plasma lipid compound levels collected at 
baseline. Lastly, it has most recently been proposed that researchers can combine 
psychopathology scores and metabolic profiling in order to categorize patients with dissimilar 
clinical diagnoses (first-episode psychosis, schizophrenia, bipolar disorder) into prognostic 
subgroups based on their expected temporal course of illness following remission (Joaquim 
et al., 2020). 
6.5.3. Identification of Biological Mechanisms Underscoring the Relationships 
between Body Mass and Treatment Outcome in First-Episode Schizophrenia 
Following the characterization of different proposed weight gain trajectories in relation to 
other metabolic syndrome changes and their effects on clinical outcome, we aim to put 
emphasis on the identification of plausible biological mechanisms underscoring these 
associations. In particular, a major focus will be on blood-based biomarkers including 
hormones and signalling proteins involved in appetite regulation and their associations with 
body mass, weight gain and treatment outcome in our first-episode patient sample (Chapters 
II, III).  
Initial exposure to antipsychotics, as well as the associated development of weight gain in 
treatment-naive schizophrenia patients, exerts individual and additive effects on the 
expression of both pro- and anti-inflammatory cytokines (Haring et al., 2015; Petrikis et al., 
2015; Juncal-Ruiz et al., 2018). These changes in cytokine profiles could be related to 
improvement in psychopathology severity associated with weight gain in treatment-naive 
first-episode schizophrenia patients (Haring et al., 2015; Dahan et al., 2018). In a similar 
fashion, an elevation in leptin and decrease in adiponectin as well as ghrelin levels over the 
initial course of treatment in first-episode schizophrenia patients could in part mediate a 




(Atmaca et al., 2003, 2007; Perez-Iglesias et al., 2008; Basoglu et al., 2010; Nurjono et al., 
2014; Balotsev et al., 2019).  
However, the complex inter-active effects of both antipsychotic exposure and weight gain on 
the trajectories of these diverse cellular mediators remain poorly understood and subject to 
further inquiry. Importantly, acute alterations in certain hormones and cytokines (e.g. IL-2, IL-
6) over the course of treatment in first-episode schizophrenia could represent a state-related 
phenomenon, while persistent elevation in other inflammatory markers such as tumour 
necrosis factor alpha (TNF-a) and C-reactive protein (CRP), compounded by weight gain 
may be largely “trait-related” (Miller et al., 2011; Fernandes et al., 2016; Capuzzi et al., 
2017). In addition, elevated CRP levels have been correlated with more severe negative 
symptoms, catatonic features and higher levels of aggression (Barzilay et al., 2016; Orsolini 
et al., 2018). This hints at more complex, inter-related metabolic pathways linking lipid 
abnormalities, inflammation and aberrant immune activation with increased illness severity in 
schizophrenia. 
6.5.4. Characterization of Brain Structural Changes in Relation to Metabolic Risk and 
Clinical Outcome in First-Episode Schizophrenia  
Our research to date has identified promising subcortical brain regions and white matter 
tracts known to form part of a “core eating network” in humans (Chen et al., 2016) as 
illustrated in Figure 1. The doctoral research presented in this dissertation provides the 
scientific rationale for extending our focus on structural neuroimaging to include 
connectomics approaches used to evaluate brain-based biomarkers in relation to metabolic 
risk and treatment outcome in first-episode schizophrenia spectrum disorders (Clementz et 
al., 2016). The need to define these neurobiological profiles based in part on brain structural 
assessment is based in part on their limited overlap with exiting clinical models for 
schizophrenia, which often do not adhere to existing diagnostic structures for the disorder 




In a recent study, Chand and colleagues (2020) used machine learning to describe two 
distinct brain structural signatures using structural MRI data obtained from schizophrenia 
patients (n=307) and healthy controls (n=364). In brief, the first brain structural signature was 
characterized by widespread grey matter volume reductions (including the medial frontal, 
temporal and insular cortices) which correlated with a longer duration of illness, poorer 
educational attainment, and poorer premorbid adjustment. In comparison, the second brain 
structural signature was characterized by relatively normal and stable neuroanatomy, 
despite increased basal ganglia and internal capsule volumes, which could not be ascribed 
to treatment exposure (Chand et al., 2020). In this setting, we aim to use a similar approach 
to explore the effects of treatment exposure on brain structure in our first-episode patient 
cohort. In particular, we aim to focus on three major structural neuroimaging outcomes, i.e. 
global cortical thickness, total white matter, and basal ganglia volumes. In addition, we aim 
to explore how these associations are related to clinical outcomes and side-effect profiles 
over 24 months of treatment.  
In a follow-up step, we aim to use connectomics data to understand these proposed biotypes 
in terms of real-world interconnected brain network (Crossley et al., 2017). In an earlier study 
by Zalesky and colleagues (2012), the authors used network-based statistics to characterize 
impaired connectivity in schizophrenia patients as an expansively disrupted brain sub-
network which mostly consisted of fronto-temporal and occipito-temporal disconnections. 
Using our available neuroimaging data obtained across two first-episode patient cohorts, we 
aim to assess path lengths (i.e. distances between each node pair) and then calculate both 
global and local efficiency as common measures used in prior studies of schizophrenia 
patients (Zalesky et al., 2012; Zhang et al., 2015; Crossley et al., 2017) with mixed results. 
Importantly, the connections between brain regions expressed as different connectivity 
profiles may assist clinicians one day in disease staging, clinical prognostication and 




That being said, we do acknowledge that the postulated “core eating network” (Chen et al., 
2016) remains to be extensively validated in a formal manner. Nevertheless, the present 
neuroimaging research provides important evidence to support the involvement not only of 
specific sub-cortical brain regions in the regulation of appetite, satiety and reward (Chapter 
V) but also the white matter tracts that connect them (Chapter IV). It is envisioned that 
extension of our brain structural imaging research over time will reveal novel insights into the 
regulation of these inter-related networks towards the standardization of specific brain 










Figure 1. Diagrammatical representation of cortical and sub-cortical neurobiological regions 
implicated as part of an extended “core eating network” (CEN) in humans, including the 
white matter tracts which connect these diverse brain areas involved in the regulation of 
appetite, satiety, emotion, and reward. The white matter tracts overlap with those identified 
and described in our DTI study (Chapter V). The cortical and sub-cortical areas were mostly 
selected from available regions of interest (ROI) we considered in sub-study IV (Chapter V) 
where we elected to focus on the hippocampus. The white matter tracts visible in this 
diagram include the superior fronto-occipital fasciculus, corpus callosum (which includes the 
genu, body and splenium), fornix (including fornix crus/stria terminalis), cingulum bundle, 
and uncinate fasciculus. The cortical areas include the prefrontal lobe, orbito-frontal cortex, 
dorso-lateral prefrontal cortex, and temporal pole. The sub-cortical areas included the 
caudate, ventral striatum, amygdala, brain stem, ventral tegmental area, ventral 




6.6. GENERAL CONCLUSIONS 
In conclusion, our findings suggest that weight gain over the first 12 months of assured 
treatment is a predictor of favourable clinical outcomes in first-episode schizophrenia 
spectrum disorders. This effect extends across multiple domains and is not a reflection of 
treatment compliance, but rather hints at complex inter-relationship between metabolic 
syndrome risk factors, clinical presentation and outcome in first-episode schizophrenia. In 
particular, involvement of brain structure and the connection between different regions of a 
“core eating network” in our patient sample constitutes an important research development. 
In addition, we provide novel evidence in support of low body mass index, and by extension, 
failure to gain weight as unfavourable prognostic markers in first-episode patients, 
particularly those who use substances. Our research thus provides the scientific basis for an 
extended application of metabolic assessment beyond cardiovascular risk stratification to 
include clinical prognostication and prediction of treatment outcome. The concurrent 
assessment of clinical and metabolic features in relation to brain structure and function could 
hold promise in optimizing treatment based on individual patient needs in those with first-
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website for access to the online Health Research Approval Process, see: https://www.westerncape.gov.za/general-publication/health-research-
approval-process. Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and instructions, please visit: Forms and Instructions on our HREC
website https://applyethics.sun.ac.za/ProjectView/Index/6144  
If you have any questions or need further assistance, please contact the HREC office at 021 938 9677.
  
Yours sincerely,
Mr. Francis Masiye ,
HREC Coordinator,
Health Research Ethics Committee 2 (HREC2).
National Health Research Ethics Council (NHREC) Registration Number:
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REC-130408-012 (HREC1)·REC-230208-010 (HREC2)
Federal Wide Assurance Number: 00001372
Office of Human Research Protections (OHRP) Institutional Review Board (IRB) Number:
IRB0005240 (HREC1)·IRB0005239 (HREC2)
 
The Health Research Ethics Committee (HREC) complies with the SA National Health Act No. 61 of 2003 as it pertains to health research. The
HREC abides by the ethical norms and principles for research, established by theWorld Medical Association (2013). Declaration of Helsinki:
Ethical Principles for Medical Research Involving Human Subjects;the South African Department of Health (2006). Guidelines for Good
Practice in the Conduct of Clinical Trials with Human Participants in South Africa (2nd edition); as well as the Department of Health
(2015). Ethics in Health Research: Principles, Processes and Structures (2nd edition).
 
The Health Research Ethics Committee reviews research involving human subjects conducted or supported by the Department of Health and
Human Services, or other federal departments or agencies that apply the Federal Policy for the Protection of Human Subjects to such research
(United States Code of Federal Regulations Title 45 Part 46); and/or clinical investigations regulated by the Food and Drug Administration
(FDA) of the Department of Health and Human Services.
 





























The final plagiarism report outlined and summarized for the doctoral studies described in this 
dissertation was created based on its full contents excluding the individual sub-studies in 
their official published format. This executive decision was motivated by the observation that 
inclusion of said publications resulted in a disproportionately high similarity index due to their 
contents being picked up as falling outside the contents of the dissertation. It was therefore 
elected to exclude the formal publications from the final dissertation submitted via the 
Turnitin portal. The final index score is therefore presented as a more appropriate reflection 
of the similarity of the research to existing publications and online sources. This report also 
represents the final scores obtained following resubmission of the revised dissertation 
submitted to the doctoral office following independent examiner review. 
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